[{"Element":"<div class=\"WordSection1\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\r I<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL solution for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each mL of the solution\r contains 600 IU (equivalent to 44 micrograms) follitropin alfa*.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 300 IU (equivalent to 22 micrograms) follitropin alfa in 0.5 mL\r solution for injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 450 IU (equivalent to 33 micrograms) follitropin alfa in 0.75 mL\r solution for injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap 900 IU\/1.5 mL\r solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 900 IU (equivalent to 66 micrograms) follitropin alfa in 1.5 mL\r solution for injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">*Follitropin alfa<\/span><span lang=\"EN-GB\" style=\"color:black\"> (recombinant human follicle\u2011stimulating\r hormone [r\u2011hFSH]) is produced in Chinese Hamster Ovary Cells\r (CHO DHFR<sup>-<\/sup>) by recombinant DNA technology.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPSMT\",serif'>Excipient(s)\r with known effect:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap contains 0.02 mg per mL of benzalkonium chloride<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap <\/span><span lang=\"EN-GB\" style=\"color:black\">contains\r <\/span><span lang=\"EN-GB\" style=\"color:black\">10.0 mg per mL of benzyl alcohol<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For the full list of\r excipients, see section 6.1.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Solution for\r injection (injection).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Clear, colourless\r solution.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The pH of the solution\r is 6.8-7.2.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">In adult women<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Anovulation (including\r polycystic ovarian syndrome) in women who have been unresponsive to treatment\r with clomifene citrate.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Stimulation of multifollicular\r development in women undergoing superovulation for assisted reproductive\r technologies (ART) such as <i>in vitro <\/i>fertilisation (IVF), gamete\r intra-fallopian transfer and zygote intra\u2011fallopian transfer.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Ovaleap in association with a\r luteinising hormone (LH) preparation is recommended for the stimulation of\r follicular development in women with severe LH and FSH deficiency. In clinical\r trials these patients were defined by an endogenous serum LH level\r &lt; 1.2 IU\/L.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">In adult men<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Ovaleap is indicated for\r the stimulation of spermatogenesis in men who have congenital or acquired\r hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin\r (hCG) therapy.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2     Posology\r and method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Treatment with follitropin alfa should be initiated under\r the supervision of a physician experienced in the treatment of fertility\r disorders.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Posology<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The dose\r recommendations given for follitropin alfa are those in use for urinary FSH.\r Clinical assessment of follitropin alfa indicates that its daily doses,\r regimens of administration and treatment monitoring procedures should not be\r different from those currently used for urinary FSH\u2011containing medicinal\r products. It is advised to adhere to the recommended starting doses indicated\r below.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Comparative clinical\r studies have shown that on average patients require a lower cumulative dose and\r shorter treatment duration with follitropin alfa compared with urinary FSH.\r Therefore, it is considered appropriate to give a lower total dose of\r follitropin alfa than generally used for urinary FSH, not only in order to\r optimise follicular development but also to minimise the risk of unwanted\r ovarian hyperstimulation (see section 5.1).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Women with\r anovulation (including polycystic ovarian syndrome)<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Follitropin alfa may be\r given as a course of daily injections. In menstruating women treatment should\r commence within the first 7 days of the menstrual cycle.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A commonly used regimen\r commences at 75\u2011150 IU FSH daily and is increased preferably by 37.5\r or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain\r an adequate, but not excessive, response. Treatment should be tailored to the\r individual patient\u2019s response as assessed by measuring follicle size by\r ultrasound and\/or oestrogen secretion. The maximal daily dose is usually not\r higher than 225 IU FSH. If a patient fails to respond adequately after\r 4 weeks of treatment, that cycle should be abandoned and the patient\r should undergo further evaluation after which she may recommence treatment at a\r higher starting dose than in the abandoned cycle.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">When an optimal\r response is obtained, a single injection of 250 micrograms recombinant\r human choriogonadotropin alfa (r-hCG) or 5,000 IU up to 10,000 IU hCG\r should be administered 24\u201148 hours after the last follitropin alfa\r injection. The patient is recommended to have coitus on the day of, and the day\r following, hCG administration. Alternatively intrauterine insemination (IUI)\r may be performed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If an excessive\r response is obtained, treatment should be stopped and hCG withheld (see section\r 4.4). Treatment should recommence in the next cycle at a dose lower than that\r of the previous cycle.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Women undergoing ovarian stimulation for multiple\r follicular development prior to in vitro fertilisation or other ART<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">A commonly used regimen for superovulation involves the\r administration of 150\u2011225 IU of follitropin alfa daily, commencing\r on days 2 or 3 of the cycle. Treatment is continued until adequate follicular\r development has been achieved (as assessed by monitoring of serum oestrogen\r concentrations and\/or ultrasound examination), with the dose adjusted according\r to the patient\u2019s response, to usually not higher than 450 IU daily. In\r general adequate follicular development is achieved on average by the tenth day\r of treatment (range 5 to 20 days).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A single injection of\r 250 micrograms r\u2011hCG or 5,000 IU up to 10,000 IU hCG is\r administered 24\u201148 hours after the last follitropin alfa injection\r to induce final follicular maturation.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Down\u2011regulation\r with a gonadotropin\u2011releasing hormone (GnRH) agonist or antagonist is now\r commonly used in order to suppress the endogenous LH surge and to control tonic\r levels of LH. In a commonly used protocol, follitropin alfa is started\r approximately 2 weeks after the start of agonist treatment, both being\r continued until adequate follicular development is achieved. For example,\r following two weeks of treatment with an agonist, 150\u2011225 IU\r follitropin alfa are administered for the first 7 days. The dose is then\r adjusted according to the ovarian response.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Overall experience with\r IVF indicates that in general the treatment success rate remains stable during\r the first four attempts and gradually declines thereafter.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Women with\r anovulation resulting from severe LH and FSH deficiency<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In LH and FSH deficient\r women (hypogonadotropic hypogonadism), the objective of follitropin alfa\r therapy in association with lutropin alfa is to develop a single mature\r Graafian follicle from which the oocyte will be liberated after the\r administration of hCG. Follitropin alfa should be given as a course of daily\r injections simultaneously with lutropin alfa. Since these patients are\r amenorrhoeic and have low endogenous oestrogen secretion, treatment can\r commence at any time.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A recommended regimen\r commences at 75 IU of lutropin alfa daily with 75\u2011150 IU FSH.\r Treatment should be tailored to the individual patient\u2019s response as assessed\r by measuring follicle size by ultrasound and oestrogen response.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If an FSH dose increase\r is deemed appropriate, dose adaptation should preferably be after 7\u201114 day\r intervals and preferably by 37.5\u201175 IU increments. It may be\r acceptable to extend the duration of stimulation in any one cycle to up to\r 5 weeks.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">When an optimal\r response is obtained, a single injection of 250 micrograms r\u2011hCG or\r 5,000 IU up to 10,000 IU hCG should be administered 24\u201148 hours\r after the last follitropin alfa and lutropin alfa injections. The patient is\r recommended to have coitus on the day of, and on the day following, hCG\r administration. Alternatively, IUI may be performed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Luteal phase support\r may be considered since lack of substances with luteotropic activity (LH\/hCG)\r after ovulation may lead to premature failure of the corpus luteum.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If an excessive\r response is obtained, treatment should be stopped and hCG withheld. Treatment\r should recommence in the next cycle at a dose of FSH lower than that of the\r previous cycle.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Men with\r hypogonadotropic hypogonadism<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Follitropin alfa should\r be given at a dose of 150 IU three times a week, concomitantly with hCG,\r for a minimum of 4 months. If after this period, the patient has not\r responded, the combination treatment may be continued; current clinical\r experience indicates that treatment for at least 18 months may be\r necessary to achieve spermatogenesis.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Special population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Elderly population<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There is no relevant\r use of follitropin alfa in the elderly population. Safety and effectiveness of\r follitropin alfa in elderly patients have not been established.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Renal or hepatic\r impairment<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Safety, efficacy and\r pharmacokinetics of follitropin alfa in patients with renal or hepatic\r impairment have not been established.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">There is no relevant use of follitropin alfa in the\r paediatric population.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Method of\r administration<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is intended for\r subcutaneous use. The first injection should be performed under direct medical\r supervision. Self-administration should only be performed by patients who are\r well motivated, adequately trained and have access to expert advice.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">As the multidose\r cartridge is intended for several injections, clear instructions should be\r provided to the patients to avoid misuse of the medicine.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The Ovaleap cartridge\r is designed for use in conjunction with the Ovaleap Pen only, which is\r separately available. For instructions on the administration with the<a name=\"OLE_LINK3\"> Ovaleap Pen<\/a>, see section 6.6.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Hypersensitivity to the active\r substance follitropin alfa, FSH or to any of the excipients<\/span><span lang=\"EN-GB\" style=\"color:black\">listed in section 6.1;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        tumours of the hypothalamus or\r pituitary gland;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        ovarian enlargement or ovarian cyst not\r due to polycystic ovarian syndrome;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        gynaecological haemorrhages of unknown\r aetiology;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        ovarian, uterine or mammary carcinoma.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap must not be used when an effective\r response cannot be obtained, such as:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        primary ovarian failure;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        malformations of sexual organs\r incompatible with pregnancy;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        fibroid tumours of the uterus incompatible\r with pregnancy;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        primary testicular insufficiency.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.4     Special warnings and precautions for use<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\r biological medicinal products, the trade name and batch number of the\r administered medicinal product should be clearly recorded in the patient file.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">General<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Follitropin alfa is a\r potent gonadotropic substance capable of causing mild to severe adverse\r reactions and should only be used by physicians who are thoroughly familiar\r with infertility problems and their management.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Gonadotropin therapy\r requires a certain time commitment by physicians and supportive health\r professionals, as well as the availability of appropriate monitoring\r facilities. In women, safe and effective use of follitropin alfa calls for\r monitoring of ovarian response with ultrasound, alone or preferably in\r combination with measurement of serum oestradiol levels, on a regular basis.\r There may be a degree of interpatient variability in response to FSH\r administration, with a poor response to FSH in some patients and exaggerated\r response in others. The lowest effective dose in relation to the treatment\r objective should be used in both men and women.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Porphyria<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Patients with porphyria or a family history of porphyria\r should be closely monitored during treatment with follitropin alfa.\r Deterioration or a first appearance of this condition may require cessation of\r treatment.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Treatment in\r women<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Before starting\r treatment, the couple\u2019s infertility should be assessed as appropriate and\r putative contraindications for pregnancy evaluated. In particular, patients\r should be evaluated for hypothyroidism, adrenocortical deficiency,\r hyperprolactinemia and appropriate specific treatment given.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Patients undergoing\r stimulation of follicular growth, whether as treatment for anovulatory\r infertility or ART procedures, may experience ovarian enlargement or develop\r hyperstimulation. Adherence to recommended follitropin alfa dose and regimen of\r administration and careful monitoring of therapy will minimise the incidence of\r such events. For accurate interpretation of the indices of follicle development\r and maturation, the physician should be experienced in the interpretation of\r the relevant tests.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In clinical trials, an\r increase of the ovarian sensitivity to follitropin alfa was shown when\r administered with lutropin alfa. If an FSH dose increase is deemed appropriate,\r dose adaptation should preferably be at 7\u201114 day intervals and\r preferably with 37.5\u201175 IU increments.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">No direct comparison of\r follitropin alfa\/LH versus human menopausal gonadotropin (hMG) has been\r performed. Comparison with historical data suggests that the ovulation rate\r obtained with follitropin alfa\/LH is similar to that obtained with hMG.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Ovarian\r Hyperstimulation Syndrome (OHSS)<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A certain degree of\r ovarian enlargement is an expected effect of controlled ovarian stimulation. It\r is more commonly seen in women with polycystic ovarian syndrome and usually\r regresses without treatment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In distinction to\r uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself\r with  increasing degrees of severity. It comprises marked ovarian enlargement,\r high serum sex steroids and an increase in vascular permeability which can\r result in an accumulation of fluid in the peritoneal, pleural and, rarely, in\r the pericardial cavities.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The following\r symptomatology may be observed in severe cases of OHSS: abdominal pain,\r abdominal distension, severe ovarian enlargement, weight gain, dyspnoea,\r oliguria and gastrointestinal symptoms including nausea, vomiting and\r diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration,\r electrolyte imbalances, ascites, haemoperitoneum, pleural effusions,\r hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be\r complicated by ovarian torsion or thromboembolic events such as pulmonary\r embolism, ischaemic stroke or myocardial infarction.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Independent risk\r factors for developing OHSS include polycystic ovarian syndrome high absolute\r or rapidly rising serum oestradiol levels (e.g. &gt; 900 pg\/mL or\r &gt; 3,300 pmol\/L in anovulation; &gt; 3,000 pg\/mL or\r &gt; 11,000 pmol\/L in ART) and large number of developing ovarian\r follicles (e.g. &gt; 3 follicles of \u2265 14 mm in\r diameter in anovulation; \u2265 20 follicles of\r \u2265 12 mm in diameter in ART).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Adherence to\r recommended follitropin alfa dose and regimen of administration can minimise the\r risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of\r stimulation cycles by ultrasound scans as well as oestradiol measurements are\r recommended to early identify risk factors.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There is evidence to\r suggest that hCG plays a key role in triggering OHSS and that the syndrome may\r be more severe and more protracted if pregnancy occurs. Therefore, if signs of\r ovarian hyperstimulation occur such as serum oestradiol level\r &gt; 5,500 pg\/mL or &gt; 20,200 pmol\/L and\/or\r \u2265 40 follicles in total, it is recommended that hCG be withheld\r and the patient be advised to refrain from coitus or to use barrier\r contraceptive methods for at least 4 days. OHSS may progress rapidly\r (within 24 hours) or over several days to become a serious medical event.\r It most often occurs after hormonal treatment has been discontinued and reaches\r its maximum at about 7 to 10 days following treatment. Therefore, patients\r should be followed for at least 2 weeks after hCG administration.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In ART, aspiration of\r all follicles prior to ovulation may reduce the occurrence of hyperstimulation.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Mild or moderate OHSS\r usually resolves spontaneously. If severe OHSS occurs, it is recommended that\r gonadotropin treatment be stopped if still ongoing and that the patient be\r hospitalised and appropriate therapy be started.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Multiple pregnancy<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">In patients undergoing ovulation induction, the incidence\r of multiple pregnancy is increased compared with natural conception. The\r majority of multiple conceptions are twins. Multiple pregnancy, especially of\r high order, carries an increased risk of adverse maternal and perinatal\r outcomes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">To minimise the risk of\r multiple pregnancy, careful monitoring of ovarian response is recommended.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In patients undergoing\r ART procedures the risk of multiple pregnancy is related mainly to the number\r of embryos replaced, their quality and the patient age.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The patients should be\r advised of the potential risk of multiple births before starting treatment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Pregnancy loss<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The incidence of\r pregnancy loss by miscarriage or abortion is higher in patients undergoing\r stimulation of follicular growth for ovulation induction or ART than following\r natural conception.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Ectopic pregnancy<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Women with a history of\r tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained\r by spontaneous conception or with fertility treatments. The prevalence of\r ectopic pregnancy after ART, was reported to be higher than in the general\r population.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Reproductive system\r neoplasms<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There have been reports\r of ovarian and other reproductive system neoplasms, both benign and malignant,\r in women who have undergone multiple treatment regimens for infertility\r treatment. It is not yet established whether or not treatment with\r gonadotropins increases the risk of these tumours in infertile women.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Congenital\r malformation<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The prevalence of\r congenital malformations after ART may be slightly higher than after\r spontaneous conceptions. This is thought to be due to differences in parental\r characteristics (e.g. maternal age, sperm characteristics) and multiple\r pregnancies.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Thromboembolic\r events<\/span><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In women with recent or\r ongoing thromboembolic disease or women with generally recognised risk factors\r for thromboembolic events, such as personal or family history, treatment with\r gonadotropins may further increase the risk for aggravation or occurrence of\r such events. In these women, the benefits of gonadotropin administration need\r to be weighed against the risks. It should be noted however that pregnancy\r itself as well as OHSS also carry an increased risk of thromboembolic events.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Treatment in men<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Elevated endogenous FSH\r levels are indicative of primary testicular failure. Such patients are\r unresponsive to follitropin alfa\/hCG therapy. Follitropin alfa should not be\r used when an effective response cannot be obtained.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Semen analysis is\r recommended 4 to 6 months after the beginning of treatment as part of the\r assessment of the response.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Benzalkonium\r chloride content<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap contains 0.02 mg\/mL of benzalkonium chloride<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Benzyl\r alcohol content<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ovaleap\r contains <\/span><span lang=\"EN-GB\">10.0 mg per mL benzyl alcohol<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Benzyl\r alcohol may cause allergic reactions.<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">High volumes\r should be used with caution and only if necessary, especially in subjects with\r liver or kidney impairment as well as in pregnant women or while\r breast-feeding, because of the risk of accumulation and toxicity (metabolic\r acidosis).<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Sodium\r content<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap contains less than 1 mmol sodium (23 mg)\r per dose, that is to say essentially \u201csodium\u00adfree\u201d.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">4.5     Interaction with other medicinal products\r and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Concomitant use of follitropin alfa with other medicinal\r products used to stimulate ovulation (e.g. hCG, clomifene citrate) may\r potentiate the follicular response, whereas concurrent use of a GnRH agonist or\r antagonist to induce pituitary desensitisation may increase the dose of\r follitropin alfa needed to elicit an adequate ovarian response. No other\r clinically significant medicinal product interaction has been reported during\r follitropin alfa therapy.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Pregnancy<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There is no indication\r for use of Ovaleap during pregnancy. Data on a limited number of exposed\r pregnancies (less than 300 pregnancy outcomes) indicate no malformative or\r foeto\/neonatal toxicity of follitropin alfa.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">No teratogenic effect\r has been observed in animal studies (see section 5.3). In case of exposure\r during pregnancy, clinical data are not sufficient to exclude a teratogenic\r effect of follitropin alfa.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Breast\u2011feeding<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is not\r indicated during breast\u2011feeding.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Fertility<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is indicated\r for use in infertility (see section 4.1).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Ovaleap has no or negligible influence on\r the ability to drive and use machines.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Summary of the\r safety profile<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The most commonly\r reported adverse reactions are headache, ovarian cysts and local injection site\r reactions (e.g. pain, erythema, haematoma, swelling and\/or irritation at the\r site of injection).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Mild or moderate OHSS\r has been commonly reported and should be considered as an intrinsic risk of the\r stimulation procedure. Severe OHSS is uncommon (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Thromboembolism may\r occur very rarely (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Tabulated list of\r adverse reactions<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">The adverse reactions are ranked under heading of frequency using\r the following convention: very<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">common (\u22651\/10), common (\u22651\/100 to &lt;1\/10), uncommon (\u22651\/1,000\r to &lt;1\/100), rare (\u22651\/10,000 to<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">&lt;1\/1,000), very rare (&lt;1\/10,000) and not known (cannot be\r estimated from the available data). Within<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">each frequency grouping, adverse reactions are presented in order of\r decreasing seriousness.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Treatment in women<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td colspan=\"3\" style=\"width:460.6pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\r   1: Adverse reactions in women<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">System\r   organ class<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Adverse\r   reaction<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Immune\r   system disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Mild to severe hypersensitivity reactions, including anaphylactic\r   reactions and shock<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Nervous\r   system disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Headache<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Thromboembolism (both in association with and separate\r   from OHSS)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Exacerbation or aggravation of asthma<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common:<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Abdominal pain, abdominal distension, abdominal\r   discomfort, nausea, vomiting, diarrhoea<\/span><\/p> <\/td> <\/tr> <tr> <td rowspan=\"4\" style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Reproductive system and breast disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovarian cysts<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Mild or moderate OHSS (including associated\r   symptomatology)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Severe OHSS (including associated symptomatology) (see\r   section 4.4)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Complication of severe OHSS<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">General\r   disorders and administration site conditions<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Injection site reactions (e.g. pain, erythema, haematoma,\r   swelling and\/or irritation at the site of injection)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><i><span lang=\"EN-GB\" style=\"color:black\">Treatment in men<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td colspan=\"3\" style=\"width:460.6pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\r   2: Adverse reactions in men<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">System\r   organ class<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Adverse\r   reaction<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Immune\r   system disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Mild to severe hypersensitivity reactions, including\r   anaphylactic reactions and shock<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Exacerbation or aggravation of asthma<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common:<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Acne<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Reproductive system and breast disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Gynaecomastia, varicocele<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">General\r   disorders and administration site conditions<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Injection site reactions (e.g. pain, erythema, haematoma,\r   swelling and\/or irritation at the site of injection)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Investigations<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Weight gain<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\r authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:lightgrey\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The effects of an\r overdose of follitropin alfa are unknown, nevertheless, there is a possibility\r that OHSS may occur (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pharmacotherapeutic\r group: Sex hormones and modulators of the genital systems, gonadotropins, ATC\r code: G03GA05.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap<\/span><span lang=\"EN-GB\" style=\"color:black\"> is a biosimilar medicinal product. Detailed\r information is available on the website of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:black;\r text-decoration:none\">http:\/\/www.ema.europa.eu<\/span><\/a><span style=\"color:black\">.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Pharmacodynamic\r effects<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In women, the most important\r effect resulting from parenteral administration of FSH is the development of\r mature Graafian follicles. In women with anovulation, the object of follitropin\r alfatherapy is to develop a single\r mature Graafian follicle from which the ovum will be liberated after the\r administration of hCG.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Clinical efficacy\r and safety in women<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In clinical trials,\r patients with severe FSH and LH deficiency were defined by an endogenous serum\r LH level &lt; 1.2 IU\/L as measured in a central laboratory. However,\r it should be taken into account that there are variations between LH\r measurements performed in different laboratories.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In clinical studies\r comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 3 below)\r and in ovulation induction, follitropin alfa was more potent than urinary FSH\r in terms of a lower total dose and a shorter treatment period needed to trigger\r follicular maturation.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In ART, follitropin\r alfa at a lower total dose and shorter treatment period than urinary FSH,\r resulted in a higher number of oocytes retrieved when compared to urinary FSH.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Table 3: Results of\r study GF 8407 (randomised parallel group study comparing efficacy and safety of\r follitropin alfa with urinary FSH in ART)<\/span><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:402.3pt;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"536\"> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:106.3pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">follitropin\r   alfa<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">(n = 130)<\/span><\/p> <\/td> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">urinary FSH<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">(n = 116)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Number of oocytes retrieved<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">11.0 \u00b1 5.9<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">8.8 \u00b1 4.8<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Days of FSH stimulation required<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">11.7 \u00b1 1.9<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">14.5 \u00b1 3.3<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Total dose of FSH required (number of FSH 75 IU\r   ampoules)<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">27.6 \u00b1 10.2<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">40.7 \u00b1 13.6<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Need to increase the dose (%)<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">56.2<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">85.3<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Differences between the\r 2 groups were statistically significant (p &lt; 0.05) for all\r criteria listed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Clinical efficacy\r and safety in men<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In men deficient in\r FSH, follitropin alfa administered concomitantly with hCG for at least\r 4 months induces spermatogenesis.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Following intravenous administration,\r follitropin alfa is distributed to the extracellular fluid space with <\/span><span lang=\"EN-GB\" style=\"color:black\">an initial half-life of around 2 hours and\r eliminated from the body with a terminal half-life of about one day. The steady\r state volume of distribution and total clearance are 10 L and 0.6 L\/h,\r respectively. One\u2011eighth of the follitropin alfa dose is excreted in the\r urine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">Following subcutaneous administration, the absolute\r bioavailability is about 70 %. Following repeated administration,\r follitropin alfa accumulates 3\u2011fold achieving a steady-state within 3\u20114 days.\r In women whose endogenous gonadotropin secretion is suppressed, follitropin\r alfa has nevertheless been shown to effectively stimulate follicular\r development and steroidogenesis, despite unmeasurable LH levels. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Non-clinical data reveal no special hazard for humans based\r on conventional studies of single and repeated dose toxicity and genotoxicity\r additional to that already stated in other sections of this SmPC.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Impaired fertility has\r been reported in rats exposed to pharmacological doses of follitropin alfa\r (\u2265 40 IU\/kg\/day) for extended periods, through reduced\r fecundity.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Given in high doses\r (\u2265 5 IU\/kg\/day) follitropin alfa caused a decrease in the\r number of viable foetuses without being a teratogen and dystocia similar to\r that observed with urinary Menopausal Gonadotropin (hMG). However, since Ovaleap\r is not indicated in pregnancy, these data are of limited clinical relevance.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Sodium dihydrogen\r phosphate dihydrate<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Sodium hydroxide\r (2 M) (for pH adjustment)<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Mannitol<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Methionine<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Polysorbate 20<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Benzyl alcohol<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Benzalkonium chloride<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In the absence of\r compatibility studies, this medicinal product must not be mixed with other\r medicinal products.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:red\">3<\/span><span lang=\"EN-GB\" style=\"color:black\"> years.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Shelf life<\/span><\/u><u><span lang=\"EN-GB\"> and storage conditions after first opening<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The cartridge in\u2011use\r in the pen may be stored for a maximum of 28 days. Do not store above\r 25 \u00b0C. The patient should write down in the patient diary provided with\r the Ovaleap Pen the date of first use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The pen cap must be put\r back on the pen after each injection in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store in a refrigerator\r (2 \u00b0C \u2011 8 \u00b0C).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the cartridge in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Before opening and\r within its shelf life, the medicinal product may be removed from the\r refrigerator, without being refrigerated again, for up to 3 months. Do not\r store above 25 \u00b0C. The medicinal product must be discarded if it has not\r been used after 3 months.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after first opening\r of the medicinal product, see section 6.3.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 0.5 mL of solution.<br\/>\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pack size of\r 1 cartridge and 10 injection needles.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 0.75 mL of solution..<br\/>\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pack size of\r 1 cartridge and 10 injection needles.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 1.5 mL of solution..<br\/>\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pack size of\r 1 cartridge and 20 injection needles.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and\r other handling<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">No special requirements for disposal.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The solution must not\r be used if it contains particles or if the solution is not clear.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is designed for\r use in conjunction with the Ovaleap Pen only. The instructions for use of the\r pen must be followed carefully.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge must be\r used by a single patient only.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Empty cartridges must\r not be refilled. Ovaleap cartridges are not designed to allow any other\r medicinal product to be mixed in the cartridges. Discard used needles\r immediately after injection.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Theramex Ireland Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">3<sup>rd<\/sup> Floor, <\/span><span lang=\"NL\">Kilmore House,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Park Lane, Spencer Dock,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Dublin 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">D01 YE64<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Ireland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/001<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/002<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap 900 IU\/1.5 mL\r solution for injection<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/003<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Date of first\r authorisation: 27 September 2013.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 16 May 2018.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\r information on this medicinal product <\/span><span lang=\"EN-GB\">is available on\r the website of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:\r none\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">. <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\r II<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.45pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">A.        MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS\r RESPONSIBLE FOR BATCH RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.45pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">B.        CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.45pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">C.        OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING\r AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.9pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.45pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt\"><b><span lang=\"EN-GB\">D.        <span style=\"text-transform:uppercase\">conditions or\r restrictions with regard to the safe and effective use of the medicinal product<\/span><\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"TitleB\"><span lang=\"EN-GB\">A.      MANUFACTURER OF THE BIOLOGICAL ACTIVE\r SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><u><span lang=\"EN-GB\">Name and\r address of the manufacturer of the biological active substance<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"DE\">Teva Biotech GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"DE\">Dornierstra\u00dfe 10<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"DE\">D-89079 Ulm<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Germany<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><u><span lang=\"EN-GB\">Name and\r address of the manufacturers responsible for batch release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"DE\">Teva Biotech GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"DE\">Dornierstra\u00dfe 10<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"DE\">D-89079 Ulm<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Germany<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Teva\r Pharmaceuticals Europe B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Swensweg 5<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">NL-2031 GA\r Haarlem<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">The\r Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Merckle GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Graf-Arco-Stra\u00dfe\r 3<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">89079 Ulm, <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Germany<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">The printed\r package leaflet of the medicinal product must state the name and address of the\r manufacturer responsible for the release of the concerned batch.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"TitleB\"><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">B.<\/span><\/a><span lang=\"EN-GB\">      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">Medicinal\r product subject to restricted medical prescription (see Annex I: Summary of\r Product Characteristics, section 4.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND REQUIREMENTS OF\r THE MARKETING AUTHORISATION<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">\u25cf       <\/span><b><span lang=\"EN-GB\">Periodic Safety Update Reports<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><span lang=\"EN-GB\">The requirements\r for submission of periodic safety update reports for this medicinal product are\r set out in the list of Union reference dates (EURD list) provided for under\r Article 107c(7) of Directive 2001\/83\/EC and any subsequent updates published on\r the European medicines web-portal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">D.      CONDITIONS OR RESTRICTIONS WITH REGARD\r TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-28.4pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><span lang=\"EN-GB\">\u25cf       <\/span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">The MAH shall\r perform the required pharmacovigilance activities and interventions detailed in\r the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any\r agreed subsequent updates of the RMP.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><span lang=\"EN-GB\">An updated RMP\r should be submitted:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;text-indent:14.2pt\"><span lang=\"EN-GB\">\u25cf   <\/span><span lang=\"EN-GB\">At the request of the European\r Medicines Agency;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt\"><span lang=\"EN-GB\">\u25cf   <\/span><span lang=\"EN-GB\">Whenever the risk management\r system is modified, especially as the result of new information being received\r that may lead to a significant change to the benefit\/risk profile or as the\r result of an important (pharmacovigilance or risk minimisation) milestone being\r reached.<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.05pt;text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\r III<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\r AND PACKAGE LEAFLET<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\r white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">follitropin alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 300 IU (equivalent to 22 micrograms) follitropin alfa in 0.5 mL\r solution. Each mL of the solution contains 600 IU (equivalent to\r 44 micrograms) follitropin alfa.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipients: sodium dihydrogen phosphate\r dihydrate, sodium hydroxide (2 M) (for pH adjustment), mannitol, methionine,\r polysorbate 20, benzyl alcohol, benzalkonium chloride, water for injections.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:lightgrey\">Solution\r for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">1 cartridge with 0.5 mL\r solution and 10 injection needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For use only with the\r Ovaleap Pen.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Subcutaneous use<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL\r PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\r children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The cartridge in\u2011use\r in the pen may be stored for a maximum of 28 days not above 25 \u00b0C.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store in a\r refrigerator.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the cartridge in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">May be stored <span style=\"color:black\">before\r opening not above 25 \u00b0C for up to 3 months. Must be discarded if it\r has not been used after 3 months.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME\r AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Theramex Ireland Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">3<sup>rd<\/sup> Floor, <\/span><span lang=\"NL\">Kilmore House,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Park Lane, Spencer Dock,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Dublin 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">D01 YE64<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Ireland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING\r AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/001<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH\r NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS\r ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION\r IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">follitropin alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 450 IU (equivalent to 33 micrograms) follitropin alfa in 0.75 mL\r solution. Each mL of the solution contains 600 IU (equivalent to\r 44 micrograms) follitropin alfa.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipients: sodium dihydrogen phosphate\r dihydrate, sodium hydroxide (2 M) (for pH adjustment), mannitol, methionine,\r polysorbate 20, benzyl alcohol, benzalkonium chloride, water for injections.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:lightgrey\">Solution\r for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">1 cartridge with\r 0.75 mL solution and 10 injection needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For use only with the\r Ovaleap Pen.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Subcutaneous use<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL\r PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\r children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The cartridge in\u2011use\r in the pen may be stored for a maximum of 28 days not above 25 \u00b0C.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store in a\r refrigerator.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the cartridge in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">May be stored <span style=\"color:black\">before\r opening not above 25 \u00b0C for up to 3 months. Must be discarded if it\r has not been used after 3 months.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME\r AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Theramex Ireland Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">3<sup>rd<\/sup> Floor, <\/span><span lang=\"NL\">Kilmore House,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Park Lane, Spencer Dock,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Dublin 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">D01 YE64<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Ireland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING\r AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/002<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH\r NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS\r ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION\r IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode carrying\r the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN:<\/span><\/p> <p class=\"MsoNormal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;\r background:white\"> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;background:\r white;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"background:white;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL solution for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">follitropin alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 900 IU (equivalent to 66 micrograms) follitropin alfa in 1.5 mL\r solution. Each mL of the solution contains 600 IU (equivalent to\r 44 micrograms) follitropin alfa.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipients: sodium dihydrogen phosphate\r dihydrate, sodium hydroxide (2 M) (for pH adjustment), mannitol, methionine,\r polysorbate 20, benzyl alcohol, benzalkonium chloride, water for injections.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black;background:lightgrey\">Solution\r for injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">1 cartridge with\r 1.5 mL solution and 20 injection needles<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For use only with the\r Ovaleap Pen.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Subcutaneous use<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL\r PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of\r children.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The cartridge in\u2011use\r in the pen may be stored for a maximum of 28 days not above 25 \u00b0C.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store in a\r refrigerator.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the cartridge in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">May be stored <span style=\"color:black\">before\r opening not above 25 \u00b0C for up to 3 months. Must be discarded if it\r has not been used after 3 months.<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL\r PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\r DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME\r AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Theramex Ireland Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">3<sup>rd<\/sup> Floor, <\/span><span lang=\"NL\">Kilmore House,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Park Lane, Spencer Dock,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Dublin 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">D01 YE64<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Ireland<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING\r AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/003<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH\r NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS\r ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION\r IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode\r carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN:<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN:<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\r PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTRIDGE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME\r OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">follitropin alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SC<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD\r OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY\r DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH\r NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS\r BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">0.5 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\r PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTRIDGE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME\r OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">follitropin alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SC<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD\r OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY\r DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH\r NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS\r BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">0.75 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM\r PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTRIDGE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME\r OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL injection<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">follitropin alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SC<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD\r OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY\r DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH\r NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">Batch<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS\r BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><span lang=\"EN-GB\">1.5 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package\r leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;background:white\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Ovaleap\r 900 IU\/1.5 mL solution for injection<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">follitropin\r alfa<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully\r before you start using this medicine because it contains important information\r for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\r again. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your\r doctor, pharmacist or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-        This medicine has been prescribed for you only. Do not pass\r it on to others. It may harm them, even if their signs of illness are the same\r as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor, pharmacist or nurse.<\/span><span lang=\"EN-GB\">This\r includes any possible side effects not listed in this leaflet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">What is in this leaflet<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.       What Ovaleap is and what it is used for<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.       What you need to know before you use Ovaleap <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.       How to use Ovaleap<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.       How to store Ovaleap<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">1.       What\r Ovaleap is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What Ovaleap\r is<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">This medicine<\/span><span lang=\"EN-GB\"> contains <\/span><span lang=\"EN-GB\">the active substance follitropin\r alfa, which is almost identical to a natural hormone produced by your body\r called \u201cfollicle\u2011stimulating hormone\u201d (FSH). FSH is a gonadotropin, a\r type of hormone that plays an important role in human fertility and\r reproduction. In women, FSH is needed for the growth and development of the\r sacs (follicles) in the ovaries that contain the egg cells. In men, FSH is\r needed for the production of sperm.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What Ovaleap\r is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\">In adult\r women, Ovaleap is used:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        to help ovulation (release of a mature egg cell from the\r follicle) in women that cannot ovulate and that have not responded to treatment\r with a medicine called \u201cclomifene citrate\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        to help follicles develop in women undergoing assisted\r reproductive technology procedures (procedures that may help you to become\r pregnant) such as \u201c<i>in vitro <\/i>fertilisation\u201d, \u201cgamete intra\u2011fallopian\r transfer\u201d or \u201czygote intra\u2011fallopian transfer\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        in combination with a medicine called \u201clutropin alfa\u201d (a\r version of another gonadotropin, \u201cluteinising hormone\u201d or LH) to help ovulation\r in women that are not ovulating because their body is producing too little FSH\r and LH.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">In adult men, Ovaleap is used:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        in combination with a medicine called \u201chuman chorionic gonadotropin\u201d\r (hCG) to help produce sperm in men that are infertile due to low levels of\r certain hormones.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.       What you need to know before you use Ovaleap<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not use\r Ovaleap:<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        if you are allergic to follitropin alfa, Follicle Stimulating\r Hormone (FSH) or any of the other ingredients of <\/span><span lang=\"EN-GB\">this\r medicine (listed in section 6)<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        if you have a tumour in your hypothalamus or pituitary\r gland (parts of the brain).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        if you are a <b><i>woman <\/i><\/b>with:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt\"><span lang=\"EN-GB\">- large ovaries\r or sacs of fluids within the ovaries (ovarian cysts) of unknown origin.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt\"><span lang=\"EN-GB\">- unexplained\r vaginal bleeding.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt\"><span lang=\"EN-GB\">- cancer in your\r ovaries, womb or breasts.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt\"><span lang=\"EN-GB\">- any condition\r that usually makes normal pregnancy impossible, such as ovarian failure (early menopause),\r fibroid tumours of the womb or malformed reproductive organs.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2022        if you are a <b><i>man<\/i><\/b>\r with:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt\"><span lang=\"EN-GB\">- testicular\r failure that is not treatable.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use <\/span><span lang=\"EN-GB\">this\r medicine if any of the above applies to you. If you are not sure, talk to your\r doctor or pharmacist before using this medicine.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Before the\r treatment is started you and your partner\u2019s fertility should be evaluated by a\r doctor experienced in treating fertility disorders.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Porphyria<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor before you start\r treatment, if you or any member of your family have porphyria. This is a\r condition that may be passed on from parents to children which means that you\r have an inability to break down porphyrins (organic compounds).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor straight away if:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        your skin becomes fragile and easily blistered, especially\r skin that has been frequently in the sun, and\/or<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2022        you have stomach, arm or leg pain.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you experience the above symptoms your\r doctor may recommend that you stop treatment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Ovarian Hyper\u2011Stimulation Syndrome\r (OHSS)<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are a woman, this medicine increases\r your risk of developing OHSS. This is when your follicles develop too much and\r become large cysts.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Talk to your doctor straight away if:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        you get pain in the lower part of the abdomen (belly),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        you gain any weight rapidly,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        you feel sick or are vomiting,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        you have difficulty in breathing.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you experience the above symptoms your\r doctor might ask you to stop using this medicine (see also section 4<\/span><span lang=\"EN-GB\"> under <\/span><span lang=\"EN-GB\">\u201cSerious side effects in women\").<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are not ovulating and if the\r recommended dose and timing are followed, the occurrence of OHSS is less\r likely. Ovaleap treatment seldom causes severe OHSS unless the medicine that is\r used for final follicular maturation (containing human chorionic gonadotropin,\r hCG) is given. If you are developing OHSS your doctor may not give you any hCG\r in this treatment cycle. You may be told not to have sex or to use a barrier\r contraceptive method for at least 4 days.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Multiple pregnancy<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">When using <\/span><span lang=\"EN-GB\">this\r medicine<\/span><span lang=\"EN-GB\">, you have a higher risk of being pregnant with\r more than one child (i.e. \u201cmultiple pregnancy\u201d, typically twins) than if you\r conceived naturally. Multiple pregnancy may lead to medical complications for\r you and your babies. You can reduce the risk of multiple pregnancy by using the\r right dose of <\/span><span lang=\"EN-GB\">this medicine<\/span><span lang=\"EN-GB\"> at\r the right times. When undergoing assisted reproductive technology the risk of\r having a multiple pregnancy is related to your age, the quality and number of fertilised\r eggs or embryos placed inside you.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Miscarriage<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">You are more likely to have a miscarriage\r than the average woman when undergoing assisted reproductive technology or\r stimulation of your ovaries to produce eggs.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Ectopic pregnancy<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">You are more likely to have a pregnancy\r outside the womb (an ectopic pregnancy) than the average woman when undergoing\r assisted reproductive technology and if you have damaged fallopian tubes.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Birth defects<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">When being conceived by\r assisted reproductive technology, a baby may have a slightly higher risk of birth\r defects  than after natural conception. This could be related to multiple\r pregnancies or to parent characteristics such as maternal age and sperm\r characteristics.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Blood clotting problems (thromboembolic\r events)<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have ever had blood clots in your\r leg or lung, or a heart attack or stroke, or if your family have experienced\r these, inform your doctor. You might have a higher risk of these problems occurring\r or becoming worse with Ovaleap treatment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Men with too much FSH in their blood<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are a man, having too much natural FSH\r in your blood can be a sign of damaged testicles. <\/span><span lang=\"EN-GB\">This\r medicine<\/span><span lang=\"EN-GB\"> usually does not work if you have this\r problem. If your doctor decides to try Ovaleap treatment, they may monitor it\r by asking you to provide semen for analysis 4 to 6 months after starting treatment.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">T<\/span><span lang=\"EN-GB\">his medicine<\/span><span lang=\"EN-GB\"> is not indicated for use in children and adolescents <\/span><span lang=\"EN-GB\">less than 18 years of age.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Other\r medicines and Ovaleap<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Tell your doctor\r or pharmacist if you are <\/span><span lang=\"EN-GB\">using<\/span><span lang=\"EN-GB\">,\r have recently used <\/span><span lang=\"EN-GB\">or might use <\/span><span lang=\"EN-GB\">any other medicines.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        If you use Ovaleap with other medicines which help ovulation\r such as human chorionic gonadotropin (hCG) or clomifene citrate, this may\r increase the response of your follicles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        If you use Ovaleap at the same time as a\r \u201cgonadotropin-releasing hormone\u201d (GnRH) agonist or antagonist (these medicines\r reduce your sex hormone levels and stop you ovulating) you may need a higher\r dose of Ovaleap to produce follicles.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Pregnancy and\r breast\u2011feeding<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">You should not use <\/span><span lang=\"EN-GB\">this\r medicine<\/span><span lang=\"EN-GB\"> if you are pregnant or breast\u2011feeding.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Driving and\r using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">This medicine\r does not affect your ability to drive and use machines.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Ovaleap\r contains sodium, benzalkonium chloride and benzyl alcohol<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicine contains less than\r 1 mmol sodium (23 mg) per dose, that is to say essentially\r \u2018sodium-free\u2019.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">This\r medicine also contains 0.02 mg per mL of benzalkonium chloride and <\/span><span lang=\"EN-GB\">10.0 mg per mL of benzyl alcohol. Ask your doctor or pharmacist for\r advice if you have a liver or kidney disease, and if you are pregnant or\r breast-feeding. This is because large amounts of benzyl alcohol can build-up in\r your body and may cause side effects (called \u201cmetabolic acidosis\u201d).<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">3.       H<\/span><span lang=\"EN-GB\">ow to use Ovaleap<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Always use <\/span><span lang=\"EN-GB\">this medicine<\/span><span lang=\"EN-GB\"> exactly as your doctor <\/span><span lang=\"EN-GB\">or pharmacist <\/span><span lang=\"EN-GB\">has told you. Check with your\r doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">This medicine\r is given as an injection into the tissue just under the skin (subcutaneous\r injection). <\/span><span lang=\"EN-GB\">Your doctor or nurse will show you how to\r inject the medicine. If you administer this medicine to yourself, please\r carefully read and follow the \u201cInstructions for Use\u201d of the pen.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What the <\/span><span lang=\"EN-GB\">recommended<\/span><\/b><b><span lang=\"EN-GB\"> dose is<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor will decide how much medicine\r you will take and how often. The doses described below are stated in\r International Units (IU).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Women<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">If you\r are not ovulating and have irregular or no periods<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u2022        This\r medicine is usually given every day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        If you have irregular periods, start using this medicine within\r the first 7 days of your menstrual cycle. If you do not have periods, you\r can start using the medicine on any convenient day.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2022        The usual starting dose of this\r medicine is 75 to 150 IU each day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Your dose of this medicine may be increased every 7 or\r every 14 days by 37.5 to 75 IU, until you get the desired response.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2022        The maximum daily dose of this\r medicine is usually not higher than 225 IU.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        When you get the desired response, you will be given hCG or\r \u201crecombinant hCG\u201d (r\u2011hCG, an hCG made in a laboratory by a special DNA\r technique). The single injection will be 250 micrograms of r\u2011hCG or\r 5,000 to 10,000 IU of hCG, 24 to 48 hours after your last Ovaleap\r injection. The best time to have sex is on the day of the hCG injection and the\r day after. Alternatively, intrauterine insemination may be performed by placing\r the sperm into the womb cavity.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If your doctor cannot see a desired\r response after 4 weeks, that treatment cycle with Ovaleap should be\r stopped. For the following treatment cycle, your doctor will give you a higher\r starting dose of this medicine than before.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If your body responds too strongly, your\r treatment will be stopped and you will not be given any hCG [<\/span><span lang=\"EN-GB\">see also section 2 under \u201cOvarian Hyper\u2011Stimulation Syndrome (OHSS)\u201d<\/span><span lang=\"EN-GB\">]. For the following cycle, your doctor will give you a lower dose\r of Ovaleap than before.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">If you need to develop several eggs for\r collection prior to any assisted reproductive technology<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        The usual starting dose of this medicine is 150 to\r 225 IU each day, from day 2 or 3 of your menstrual cycle.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        The dose may be increased, depending on your response. The\r maximum daily dose is 450 IU.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Treatment is continued until your eggs have developed to a\r desired point. This usually takes about 10 days but can take any time\r between 5 and 20 days. Your doctor will use blood tests and\/or an\r ultrasound machine to check when this is.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        When your eggs are ready, you will be given hCG or r\u2011hCG.\r The single injection will be 250 micrograms of r\u2011hCG or 5,000 to 10,000 IU\r of hCG, 24 to 48 hours after the last Ovaleap injection. This gets your\r eggs ready for collection.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In other cases, your doctor may first stop\r you from ovulating by using a gonadotropin\u2011releasing hormone (GnRH)\r agonist or antagonist. Then Ovaleap is given approximately 2 weeks after\r the start of agonist treatment. The Ovaleap and GnRH agonist are then both\r given until your follicles develop as desired.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">If you are not ovulating, have no\r periods and have been diagnosed with very low levels of FSH and LH hormones<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        The usual starting dose of Ovaleap is 75 to 150 IU\r together with 75 IU of lutropin alfa.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2022        You will use these two medicines\r each day for up to 5 weeks.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Your dose of Ovaleap may be increased every 7 or every\r 14 days by 37.5 to 75 IU, until you get the desired response.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        When you get the desired response, you will be given hCG or\r r\u2011hCG. The single injection will be 250 micrograms of r\u2011hCG or\r 5,000 to 10,000 IU of hCG, 24 to 48 hours after your last injections\r of Ovaleap and lutropin alfa. The best time to have sex is on the day of the\r hCG injection and the day after. Alternatively, intrauterine insemination may\r be performed by placing the sperm into the womb cavity.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If your doctor cannot see a response after\r 5 weeks, that treatment cycle should be stopped. For the following cycle,\r your doctor will give you a higher starting dose of this medicine than before.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If your body responds too strongly, your\r treatment with Ovaleap will be stopped and you will not be given any hCG [<\/span><span lang=\"EN-GB\">see also section 2 under \u201cOvarian Hyper\u2011Stimulation Syndrome\r (OHSS)\u201d<\/span><span lang=\"EN-GB\">]. For the following cycle, your doctor will\r give you a lower dose of Ovaleap than before.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Men<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u2022        The\r usual dose of this medicine is 150 IU together with hCG.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2022        You will use these two medicines\r three times a week for at least 4 months.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        If you have not responded to treatment after 4 months,\r your doctor may suggest that you continue using these two medicines for at\r least 18 months.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">How are the injections given?<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicine is given as an injection into\r the tissue just under the skin (subcutaneous injection) using the Ovaleap Pen.\r The Ovaleap Pen is a device (a \u201cpen\u201d) used for giving injections into the\r tissue just under the skin.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Your doctor may\r suggest that you learn how to inject yourself with this medicine. Your doctor\r or nurse will give you instructions on how to do this and <\/span><span lang=\"EN-GB\" style=\"color:black\">you can also find instructions<\/span><span lang=\"EN-GB\"> in the separate instructions for use of the pen<\/span><span lang=\"EN-GB\">. Do not attempt to self\u2011administer this medicine without this\r training by your doctor or nurse. The very first injection of <\/span><span lang=\"EN-GB\">this medicine <\/span><span lang=\"EN-GB\">should only be given in the\r presence of a doctor or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Ovaleap solution\r for injection in cartridges has been developed for use in the Ovaleap Pen.\r You must follow the separate instructions for use of the Ovaleap Pen\r carefully. The instructions for use of the pen will be provided together with\r the Ovaleap Pen.<\/span><span lang=\"EN-GB\"> Proper treatment of your condition,\r however, requires close and constant co\u2011operation with your doctor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Discard used\r needles immediately after injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">If you use\r more Ovaleap than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The effects of using\r too much Ovaleap are unknown. Nevertheless one could expect Ovarian Hyper\u2011Stimulation\r Syndrome (OHSS) to occur, which is described in section 4 under \u201cSerious side\r effects in women\". However, the OHSS will only occur if hCG is also\r administered [see also section 2 under \u201cOvarian Hyper\u2011Stimulation\r Syndrome (OHSS)\u201d].<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">If you forget\r to use Ovaleap<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Do not use a\r double dose to make up for a forgotten dose. Please talk to your doctor as soon\r as you realise that you forgot a dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">If you have\r any further questions on the use of this medicine, ask your doctor, pharmacist <\/span><span lang=\"EN-GB\">or nurse.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><a name=\"OLE_LINK6\"><\/a><a name=\"OLE_LINK7\"><b><span lang=\"EN-GB\">4.       Possible\r side effects<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">Like all\r medicines, this medicine can cause side effects, although not everybody gets\r them.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><b><span lang=\"EN-GB\">Important\r side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><u><span lang=\"EN-GB\">Serious\r side effects in men and women<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Allergic reactions such as skin rash, raised itchy areas of\r skin and severe allergic reactions with weakness, drop in blood pressure,\r difficulty breathing and swelling of the face have been reported very rarely\r (may affect up to 1 in 10,000 people). If you think you are having this\r type of reaction, you must stop your Ovaleap injection and get medical help immediately.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><u><span lang=\"EN-GB\">Serious\r side effects in women<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Lower stomach ache together with nausea or vomiting may be\r the symptoms of Ovarian Hyper\u2011Stimulation Syndrome (OHSS). This may\r indicate that the ovaries over\u2011reacted to the treatment and that large\r ovarian cysts developed [see also section 2 under \u201cOvarian Hyper\u2011Stimulation\r Syndrome (OHSS)\u201d]. This side effect is common (may affect up to 1 in\r 10 people).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        OHSS may become severe with clearly enlarged ovaries,\r decreased urine production, weight gain, difficulty in breathing and\/or\r possible fluid accumulation in your stomach or chest. This side effect is\r uncommon (may affect up to 1 in 100 people).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Complications of OHSS such as twisting of ovaries or blood\r clotting may occur rarely (may affect up to 1 in 1,000 people).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Serious blood clotting complications (thromboembolic\r events), sometimes independent of OHSS, may be found very rarely (may affect up\r to 1 in 10,000 people). This could cause chest pain, breathlessness,\r stroke or heart attack [see also section 2 under \u201cBlood clotting problems\r (thromboembolic events)\u201d].<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><span lang=\"EN-GB\">If you notice\r any of the above-listed side effects you should immediately contact your doctor\r who may ask you to stop using Ovaleap.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Other side\r effects in women<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\">Very common<\/span><\/u><span lang=\"EN-GB\"> (<\/span><span lang=\"EN-GB\">may affect more than 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Local reactions at the injection site, such as pain,\r redness, bruising, swelling and\/or irritation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Headache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Sacs of fluid within the ovaries (ovarian cysts)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><u><span lang=\"EN-GB\">Common<\/span><\/u><span lang=\"EN-GB\"> (<\/span><span lang=\"EN-GB\">may\r affect up to 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Stomach ache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Abdominal bloating<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Abdominal cramps<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Feeling sick<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><u><span lang=\"EN-GB\">Very rare<\/span><\/u><span lang=\"EN-GB\"> (<\/span><span lang=\"EN-GB\">may\r affect up to 1 in 10,000 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Your asthma may get worse.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">Other side effects in men<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><u><span lang=\"EN-GB\">Very common<\/span><\/u><span lang=\"EN-GB\"> (<\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Local reactions at the injection site, such as pain,\r redness, bruising, swelling and\/or irritation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><u><span lang=\"EN-GB\">Common<\/span><\/u><span lang=\"EN-GB\"> (<\/span><span lang=\"EN-GB\">may\r affect up to 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Swelling of the veins above and behind the testicles (a\r varicocele)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><a name=\"OLE_LINK4\"><\/a><a name=\"OLE_LINK5\"><span lang=\"EN-GB\">\u2022        <\/span><\/a><span lang=\"EN-GB\">Breast development<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Acne<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Weight gain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><u><span lang=\"EN-GB\">Very rare<\/span><\/u><span lang=\"EN-GB\"> (<\/span><span lang=\"EN-GB\">may\r affect up to 1 in 10,000 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">\u2022        Your asthma may get worse.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Reporting of\r side effects<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, <\/span><span lang=\"EN-GB\">talk to your doctor, pharmacist or nurse.<\/span><span lang=\"EN-GB\">\r This includes any possible side effects not listed in this leaflet. You can\r also report side effects directly via <span style=\"background:lightgrey\">the\r national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><span lang=\"EN-GB\">. By reporting side effects you can help provide more information on\r the safety of this medicine.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">5.       How to store Ovaleap<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Keep <\/span><span lang=\"EN-GB\">this medicine <\/span><span lang=\"EN-GB\">out of the sight and reach of\r children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Do not use this\r medicine after the expiry date which is stated on the label and outer carton\r after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store in a refrigerator\r (2 \u00b0C \u2011 8 \u00b0C).<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the cartridge in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Before opening and\r within its shelf life, you may remove this medicine from the refrigerator,\r without being refrigerated again, for up to 3 months. Do not store above\r 25 \u00b0C. You must discard this medicine if it has not been used after\r 3 months.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Once opened, the\r cartridge in\u2011use in the pen may be stored for a maximum of 28 days.\r Do not store above 25 \u00b0C. Write down the date of first use in the patient\r diary, which will be provided with the Ovaleap Pen.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Put the pen cap back\r on the <span style=\"color:black\">Ovaleap Pen<\/span> after each injection <span style=\"color:black\">in order to protect the cartridge from light.<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Do not use this\r medicine if you notice i<\/span><span lang=\"EN-GB\">t is cloudy or there are\r particles in it.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Do not <\/span><span lang=\"EN-GB\">throw away any medicines <\/span><span lang=\"EN-GB\">via wastewater. Ask\r your pharmacist how to <\/span><span lang=\"EN-GB\">throw away <\/span><span lang=\"EN-GB\">medicines you no longer use. These measures will help protect the\r environment.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">6.       <\/span><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What Ovaleap\r contains <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substance is follitropin alfa.<br\/>\r Ovaleap 300 IU\/0.5 mL: Each cartridge contains 300 IU <span style=\"color:black\">(equivalent to 22 micrograms) <\/span>follitropin alfa\r in 0.5 mL solution.<br\/>\r Ovaleap 450 IU\/0.75 mL: Each cartridge contains 450 IU <span style=\"color:black\">(equivalent to 33 micrograms) <\/span>follitropin alfa\r in 0.75 mL solution.<br\/>\r Ovaleap 900 IU\/1.5 mL: Each cartridge contains 900 IU <span style=\"color:black\">(equivalent to 66 micrograms) <\/span>follitropin alfa\r in 1.5 mL solution.<br\/> <span style=\"color:black\">Each mL of the solution contains 600 IU\r (equivalent to 44 micrograms) follitropin alfa.<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients<\/span><span lang=\"EN-GB\">are sodium dihydrogen phosphate dihydrate, sodium hydroxide\r (2 M) (for pH adjustment), mannitol, methionine, polysorbate 20,\r benzyl alcohol, benzalkonium chloride and water for injections.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">All strengths\r listed above contain the other ingredients.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">What Ovaleap\r looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Ovaleap<\/span><span lang=\"EN-GB\"> is a\r solution for injection (injection). Ovaleap is a clear and colourless solution.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Ovaleap 300 IU\/0.5 mL is\r available in packs containing 1 cartridge and 10 injection needles.<br\/>\r Ovaleap 450 IU\/0.75 mL is available in packs containing\r 1 cartridge and 10 injection needles.<br\/>\r Ovaleap 900 IU\/1.5 mL is available in packs containing\r 1 cartridge and 20 injection needles.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Marketing\r Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Theramex Ireland Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">3<sup>rd<\/sup> Floor, <\/span><span lang=\"NL\">Kilmore House,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Park Lane, Spencer Dock,<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">Dublin 1<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"NL\">D01 YE64<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"NL\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\"><a name=\"OLE_LINK8\"><\/a><a name=\"OLE_LINK9\"><span lang=\"EN-GB\">Teva Biotech GmbH<\/span><\/a><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dornierstra\u00dfe 10<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">89079 Ulm<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Germany<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">Teva Pharmaceuticals Europe B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">Swensweg 5<\/span><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">2031 GA Haarlem<\/span><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-28.4pt\"><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">Merckle GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">Graf-Arco-Stra\u00dfe 3<\/span><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">89079 Ulm, <\/span><\/p> <p class=\"MsoNormal\" style=\"background:silver\"><span lang=\"EN-GB\" style=\"color:\r black\">Germany<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"EN-GB\">This leaflet\r was last <\/span><span lang=\"EN-GB\">revised in <\/span><\/b><span lang=\"EN-GB\">{<b>month\r YYYY<\/b>}<b>.<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\r information on this medicine is available on the European Medicines Agency web\r site: <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:none\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <\/div>","ID":"296e9317-9e70-4837-8a70-6c7f98c9bee4","Styles":"None","Classes":"['WordSection1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ","ParentId":"56a79f58-07ca-47a0-9bb9-70f89182f54e"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"28ac5ebd-985e-41b9-986f-a02987b1e71f","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"5f7ea08a-62b4-4aad-ace1-2f303b10e8e4","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"d34f29ee-75e5-4fdf-8509-c6689d660dec","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"22120ddb-76c4-42bd-ae80-9e91a71c59d6","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"7c5cb8e3-ca79-4860-8fc1-6accc4050819","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"89a7f45e-f0b4-4dc8-bb2f-4cf1eac94a91","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"6250d32f-6404-4474-aa7c-925e44912694","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"00b96984-db41-4811-a165-08d635dbf1e0","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"9309c07a-826a-41a0-aa1a-8260b083740e","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"9fcc99b5-ac1a-4bf1-86aa-c58071626fb3","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"29b69c9a-b739-4cb0-bb10-f4e7d28841a9","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"ab5e8127-5f4a-4189-8c0f-c852d6eb4253","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"7a41a78c-2d6d-47a3-88cb-001c188e6e96","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"4d1c6ae5-6078-47fc-b347-a7ce298535cb","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"f0127df7-f9bc-464f-8506-da9a20c9d519","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"b8266db1-0c5a-4ef2-b31a-b94fdbcb81fa","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"3f35c12c-2f19-4520-a9ba-4379ad3eb29f","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"48c54935-812c-4bcd-bfcf-617167295145","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"7a87b94a-a5c1-440a-87b2-11959fbe5f6c","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"579e9a13-946e-4112-8542-95b8beb1ec94","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"e2a17ad8-ef87-4f0d-8ed9-5451acd107f8","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"d81b2888-c777-40d4-b76b-04c3ef9506c4","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"9c26e457-2862-4305-9506-2187db42f3f2","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\r I<\/span><\/b><\/p>","ID":"808a3ac9-8dfe-401c-b092-f8f442420035","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":null,"IsULTag":null,"Text":"ANNEX\r I","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"8a674ffb-29c8-4c60-9b52-98fbcf97a9c6","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p>","ID":"2581a137-2a1b-4622-a24f-97e29c8327e8","Styles":"None","Classes":"['TitleA']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"SUMMARY OF PRODUCT CHARACTERISTICS","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><\/p>","ID":"3c0c502c-4a30-4060-b821-71a00021f7ee","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"1b3070f2-bd3f-4413-83cb-8a554f8cfc8f","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"b937e674-f0e2-4dc3-850f-752d977c6687","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"1b3070f2-bd3f-4413-83cb-8a554f8cfc8f"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"72cecf05-4efc-48b3-99fc-49ae344b7cad","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c71c80f8-0cc0-42d9-8f49-a93ed66e5283","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b5c7b048-c60f-400f-9dcc-eb897ecc0c17","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p>","ID":"3f8f3355-c0f3-4836-a1fb-88835eb70364","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a08d0ddf-c282-468b-86bb-6a1bc646834c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/p>","ID":"7e91d607-f198-4f43-9e20-f7e47b82fdb8","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap\r 300 IU\/0.5 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/p>","ID":"7df8714b-56ff-447f-a0f0-caaeffe01687","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap\r 450 IU\/0.75 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL solution for injection<\/span><\/p>","ID":"4932ba2a-7950-48f6-a0b1-b8c13a7b9455","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap\r 900 IU\/1.5 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b29f920a-b2d1-4c94-9ee1-b257e15cac39","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b91dddfa-47b5-48fc-b6bb-cb71934afd7c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/b><\/p>","ID":"5265de16-100d-4cf5-a21e-c44719ef3859","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"410c55d5-143a-49ee-ac23-ae95bbd67554","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each mL of the solution\r contains 600 IU (equivalent to 44 micrograms) follitropin alfa*.<\/span><\/p>","ID":"5c1c7037-fdc2-4cbc-9a63-b4cc1f80e13d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each mL of the solution\r contains 600 IU (equivalent to 44 micrograms) follitropin alfa*.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"88506772-0bf8-4fab-a35c-5c6525c1ba99","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/u><\/p>","ID":"05315da1-a175-420b-a371-13f6fb74c777","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 300 IU\/0.5 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 300 IU (equivalent to 22 micrograms) follitropin alfa in 0.5 mL\r solution for injection.<\/span><\/p>","ID":"75931c2c-cb16-4e2c-b183-839e11b530e4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each cartridge contains\r 300 IU (equivalent to 22 micrograms) follitropin alfa in 0.5 mL\r solution for injection.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1439a251-0c90-4510-9486-ddcc643000a1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/u><\/p>","ID":"8cb2f7a9-83e0-4bb5-a6b8-ff215cc5a6ed","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 450 IU\/0.75 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 450 IU (equivalent to 33 micrograms) follitropin alfa in 0.75 mL\r solution for injection.<\/span><\/p>","ID":"c0eb1d33-41c4-429a-aa1c-1fa0f1b4cb69","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each cartridge contains\r 450 IU (equivalent to 33 micrograms) follitropin alfa in 0.75 mL\r solution for injection.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"15998747-1c6f-4c6b-a882-c12c8119afc6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap 900 IU\/1.5 mL\r solution for injection<\/span><\/u><\/p>","ID":"49f3ec66-5d6a-472f-b131-86d3241de14c","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap 900 IU\/1.5 mL\r solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge contains\r 900 IU (equivalent to 66 micrograms) follitropin alfa in 1.5 mL\r solution for injection.<\/span><\/p>","ID":"1528f365-cd78-4a40-a463-e8ce513fd5b8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each cartridge contains\r 900 IU (equivalent to 66 micrograms) follitropin alfa in 1.5 mL\r solution for injection.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f001e72f-56ed-4e29-b289-3b90bde880db","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">*Follitropin alfa<\/span><span lang=\"EN-GB\" style=\"color:black\"> (recombinant human follicle\u2011stimulating\r hormone [r\u2011hFSH]) is produced in Chinese Hamster Ovary Cells\r (CHO DHFR<sup>-<\/sup>) by recombinant DNA technology.<\/span><\/p>","ID":"21dd60e5-e653-4f32-9b7b-d93fc88d4182","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"*Follitropin alfa (recombinant human follicle\u2011stimulating\r hormone [r\u2011hFSH]) is produced in Chinese Hamster Ovary Cells\r (CHO DHFR-) by recombinant DNA technology.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"995071ec-6e66-44ab-b961-8d4a66921a94","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPSMT\",serif'>Excipient(s)\r with known effect:<\/span><\/u><\/p>","ID":"dcbf950c-745a-4d4b-bad5-605ee4b31114","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Excipient(s)\r with known effect:","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap contains 0.02 mg per mL of benzalkonium chloride<\/span><\/p>","ID":"529ff649-1ce3-4d31-91c8-7cde76d4e35d","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap contains 0.02 mg per mL of benzalkonium chloride","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap <\/span><span lang=\"EN-GB\" style=\"color:black\">contains\r <\/span><span lang=\"EN-GB\" style=\"color:black\">10.0 mg per mL of benzyl alcohol<\/span><\/p>","ID":"7f05fbf0-3c5c-4388-8817-2d17377c0cf7","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap contains\r 10.0 mg per mL of benzyl alcohol","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"919c9e9b-3e6a-4c77-98e3-ba942238b945","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">For the full list of\r excipients, see section 6.1.<\/span><\/p>","ID":"32d4e278-f0ea-4cda-b016-e58910ec5110","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of\r excipients, see section 6.1.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6bebb22e-4382-48ec-afde-33ef071b986e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c778c313-4599-4004-a640-429365191a0b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/p>","ID":"4f4507a8-a102-4a73-bd5a-b5d901497210","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p>","ID":"4edcb14a-74d9-468a-ac80-039114e8a403","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Solution for\r injection (injection).<\/span><\/p>","ID":"a9ca86bc-34b9-4b90-8568-6ee4156e51a6","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Solution for\r injection (injection).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a59085f4-c996-482d-b377-62cee6420989","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Clear, colourless\r solution.<\/span><\/p>","ID":"fe0f9fcd-42dc-4db5-970e-8cdc8c884c30","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clear, colourless\r solution.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b31dda62-3ec3-4c9f-bd0f-e75b262c6005","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The pH of the solution\r is 6.8-7.2.<\/span><\/p>","ID":"ced1cbe0-f68d-4b5c-bdfc-8a4c8d8df4f2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pH of the solution\r is 6.8-7.2.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p>","ID":"8d799eaa-c065-492d-9486-52738f2e9b88","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"685aa35c-2fbd-40eb-8ac3-8d3855602449","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS<\/span><\/b><\/p>","ID":"7d416d4a-d48d-4601-a6f3-69202f2be5d5","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e5c3503a-7393-4231-8e61-d64a251c3c5f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p>","ID":"0bbb3ae5-b2de-42b6-8fcf-43d224f9f2d0","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e018c297-02d4-4786-9c5f-9af25598e985","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">In adult women<\/span><\/u><\/p>","ID":"b237dfb6-dd1a-4c25-89c0-21b7e12eaa18","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"In adult women","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><\/p>","ID":"035cf2fd-3905-4fd1-bf26-25cb4cd50f91","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Anovulation (including\r polycystic ovarian syndrome) in women who have been unresponsive to treatment\r with clomifene citrate.<\/span><\/p>","ID":"28f4fdb1-6d2f-40ac-a5cf-a48b026ef6ca","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        Anovulation (including\r polycystic ovarian syndrome) in women who have been unresponsive to treatment\r with clomifene citrate.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Stimulation of multifollicular\r development in women undergoing superovulation for assisted reproductive\r technologies (ART) such as <i>in vitro <\/i>fertilisation (IVF), gamete\r intra-fallopian transfer and zygote intra\u2011fallopian transfer.<\/span><\/p>","ID":"0cbdf6be-aa98-43cc-81e5-39401007ae59","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        Stimulation of multifollicular\r development in women undergoing superovulation for assisted reproductive\r technologies (ART) such as in vitro fertilisation (IVF), gamete\r intra-fallopian transfer and zygote intra\u2011fallopian transfer.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Ovaleap in association with a\r luteinising hormone (LH) preparation is recommended for the stimulation of\r follicular development in women with severe LH and FSH deficiency. In clinical\r trials these patients were defined by an endogenous serum LH level\r &lt; 1.2 IU\/L.<\/span><\/p>","ID":"fda5937a-f3d0-46a7-928a-20d9f21c1b17","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        Ovaleap in association with a\r luteinising hormone (LH) preparation is recommended for the stimulation of\r follicular development in women with severe LH and FSH deficiency. In clinical\r trials these patients were defined by an endogenous serum LH level\r < 1.2 IU\/L.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"10bf26cd-6869-4158-a431-4f172b938f57","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">In adult men<\/span><\/u><\/p>","ID":"7811a38d-c9bc-4a56-b8fd-c05fb94a62db","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"In adult men","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><\/p>","ID":"c7240638-c46f-4923-8562-ef9a1ec61613","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Ovaleap is indicated for\r the stimulation of spermatogenesis in men who have congenital or acquired\r hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin\r (hCG) therapy.<\/span><\/p>","ID":"7ca7df21-0058-4914-9b8b-fdaaaa688ab2","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        Ovaleap is indicated for\r the stimulation of spermatogenesis in men who have congenital or acquired\r hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin\r (hCG) therapy.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5348a148-35dd-49b4-a450-017076db23b2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2     Posology\r and method of administration<\/span><\/b><\/p>","ID":"db8a3309-c8d9-4b60-9f66-9beeab9f5bce","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology\r and method of administration","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"67a86e0c-d578-4551-9237-c5ec3967520a","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"da91b846-3daa-49f5-9991-476edc200bb3","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Treatment with follitropin alfa should be initiated under\r the supervision of a physician experienced in the treatment of fertility\r disorders.<\/span><\/p>","ID":"3b8d8d71-369c-4fc2-8ad2-4fc73cf087dc","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Treatment with follitropin alfa should be initiated under\r the supervision of a physician experienced in the treatment of fertility\r disorders.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2fecf97b-9ad1-4f22-a32d-25d6e92d8732","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Posology<\/span><\/u><\/p>","ID":"a408f680-0bb7-4e7c-bdde-4c4a52cd8d7b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4e01ede5-ef20-4d1a-8aab-1b90c3237acc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The dose\r recommendations given for follitropin alfa are those in use for urinary FSH.\r Clinical assessment of follitropin alfa indicates that its daily doses,\r regimens of administration and treatment monitoring procedures should not be\r different from those currently used for urinary FSH\u2011containing medicinal\r products. It is advised to adhere to the recommended starting doses indicated\r below.<\/span><\/p>","ID":"bbbd2763-ee13-48a2-b8d3-03bfaaaedcc9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The dose\r recommendations given for follitropin alfa are those in use for urinary FSH.\r Clinical assessment of follitropin alfa indicates that its daily doses,\r regimens of administration and treatment monitoring procedures should not be\r different from those currently used for urinary FSH\u2011containing medicinal\r products. It is advised to adhere to the recommended starting doses indicated\r below.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f65632d6-6e77-4986-8bed-f01f94a92627","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Comparative clinical\r studies have shown that on average patients require a lower cumulative dose and\r shorter treatment duration with follitropin alfa compared with urinary FSH.\r Therefore, it is considered appropriate to give a lower total dose of\r follitropin alfa than generally used for urinary FSH, not only in order to\r optimise follicular development but also to minimise the risk of unwanted\r ovarian hyperstimulation (see section 5.1).<\/span><\/p>","ID":"a982fbc0-30f0-4bb2-963f-6a35e4760046","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Comparative clinical\r studies have shown that on average patients require a lower cumulative dose and\r shorter treatment duration with follitropin alfa compared with urinary FSH.\r Therefore, it is considered appropriate to give a lower total dose of\r follitropin alfa than generally used for urinary FSH, not only in order to\r optimise follicular development but also to minimise the risk of unwanted\r ovarian hyperstimulation (see section 5.1).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2a08d862-a8fc-479c-b5db-3eef0bf86459","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Women with\r anovulation (including polycystic ovarian syndrome)<\/span><\/u><\/i><\/p>","ID":"f08b95b1-58c8-495b-bb50-2eeaa44eb792","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Women with\r anovulation (including polycystic ovarian syndrome)","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Follitropin alfa may be\r given as a course of daily injections. In menstruating women treatment should\r commence within the first 7 days of the menstrual cycle.<\/span><\/p>","ID":"84cca439-5488-4cba-9e1d-d34f46ccfeeb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Follitropin alfa may be\r given as a course of daily injections. In menstruating women treatment should\r commence within the first 7 days of the menstrual cycle.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"42ce2844-dfa3-4894-8eff-6ee20804760d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A commonly used regimen\r commences at 75\u2011150 IU FSH daily and is increased preferably by 37.5\r or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain\r an adequate, but not excessive, response. Treatment should be tailored to the\r individual patient\u2019s response as assessed by measuring follicle size by\r ultrasound and\/or oestrogen secretion. The maximal daily dose is usually not\r higher than 225 IU FSH. If a patient fails to respond adequately after\r 4 weeks of treatment, that cycle should be abandoned and the patient\r should undergo further evaluation after which she may recommence treatment at a\r higher starting dose than in the abandoned cycle.<\/span><\/p>","ID":"0c0eb566-5f20-4bb9-8271-014db9eb9c10","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A commonly used regimen\r commences at 75\u2011150 IU FSH daily and is increased preferably by 37.5\r or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain\r an adequate, but not excessive, response. Treatment should be tailored to the\r individual patient\u2019s response as assessed by measuring follicle size by\r ultrasound and\/or oestrogen secretion. The maximal daily dose is usually not\r higher than 225 IU FSH. If a patient fails to respond adequately after\r 4 weeks of treatment, that cycle should be abandoned and the patient\r should undergo further evaluation after which she may recommence treatment at a\r higher starting dose than in the abandoned cycle.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"99e7a76b-495f-4a12-9154-ffd889feab98","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">When an optimal\r response is obtained, a single injection of 250 micrograms recombinant\r human choriogonadotropin alfa (r-hCG) or 5,000 IU up to 10,000 IU hCG\r should be administered 24\u201148 hours after the last follitropin alfa\r injection. The patient is recommended to have coitus on the day of, and the day\r following, hCG administration. Alternatively intrauterine insemination (IUI)\r may be performed.<\/span><\/p>","ID":"7f43c095-1efe-49f7-afbb-f907af6b6dc8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"When an optimal\r response is obtained, a single injection of 250 micrograms recombinant\r human choriogonadotropin alfa (r-hCG) or 5,000 IU up to 10,000 IU hCG\r should be administered 24\u201148 hours after the last follitropin alfa\r injection. The patient is recommended to have coitus on the day of, and the day\r following, hCG administration. Alternatively intrauterine insemination (IUI)\r may be performed.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"52259280-9736-4fbe-8f4d-0e142a04f884","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If an excessive\r response is obtained, treatment should be stopped and hCG withheld (see section\r 4.4). Treatment should recommence in the next cycle at a dose lower than that\r of the previous cycle.<\/span><\/p>","ID":"5d197263-993c-47ae-91d7-3250b916306f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"If an excessive\r response is obtained, treatment should be stopped and hCG withheld (see section\r 4.4). Treatment should recommence in the next cycle at a dose lower than that\r of the previous cycle.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"afaee38b-36cd-43de-932b-867f093543e3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Women undergoing ovarian stimulation for multiple\r follicular development prior to in vitro fertilisation or other ART<\/span><\/u><\/i><\/p>","ID":"851f6d89-697d-41d0-bd7f-190787c39c91","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Women undergoing ovarian stimulation for multiple\r follicular development prior to in vitro fertilisation or other ART","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">A commonly used regimen for superovulation involves the\r administration of 150\u2011225 IU of follitropin alfa daily, commencing\r on days 2 or 3 of the cycle. Treatment is continued until adequate follicular\r development has been achieved (as assessed by monitoring of serum oestrogen\r concentrations and\/or ultrasound examination), with the dose adjusted according\r to the patient\u2019s response, to usually not higher than 450 IU daily. In\r general adequate follicular development is achieved on average by the tenth day\r of treatment (range 5 to 20 days).<\/span><\/p>","ID":"ebd46532-a02b-4e0b-b988-089aba5bdc5c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A commonly used regimen for superovulation involves the\r administration of 150\u2011225 IU of follitropin alfa daily, commencing\r on days 2 or 3 of the cycle. Treatment is continued until adequate follicular\r development has been achieved (as assessed by monitoring of serum oestrogen\r concentrations and\/or ultrasound examination), with the dose adjusted according\r to the patient\u2019s response, to usually not higher than 450 IU daily. In\r general adequate follicular development is achieved on average by the tenth day\r of treatment (range 5 to 20 days).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"52e04fa5-af8e-428c-96ca-dac1255bdd93","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A single injection of\r 250 micrograms r\u2011hCG or 5,000 IU up to 10,000 IU hCG is\r administered 24\u201148 hours after the last follitropin alfa injection\r to induce final follicular maturation.<\/span><\/p>","ID":"626daccc-845b-4c51-a24f-7d8ca9b3d960","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A single injection of\r 250 micrograms r\u2011hCG or 5,000 IU up to 10,000 IU hCG is\r administered 24\u201148 hours after the last follitropin alfa injection\r to induce final follicular maturation.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"548e1f6a-7a4a-4b04-ad6f-73141f3005d3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Down\u2011regulation\r with a gonadotropin\u2011releasing hormone (GnRH) agonist or antagonist is now\r commonly used in order to suppress the endogenous LH surge and to control tonic\r levels of LH. In a commonly used protocol, follitropin alfa is started\r approximately 2 weeks after the start of agonist treatment, both being\r continued until adequate follicular development is achieved. For example,\r following two weeks of treatment with an agonist, 150\u2011225 IU\r follitropin alfa are administered for the first 7 days. The dose is then\r adjusted according to the ovarian response.<\/span><\/p>","ID":"afa1d9fb-ab58-4e0b-bb90-f860f470f7da","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Down\u2011regulation\r with a gonadotropin\u2011releasing hormone (GnRH) agonist or antagonist is now\r commonly used in order to suppress the endogenous LH surge and to control tonic\r levels of LH. In a commonly used protocol, follitropin alfa is started\r approximately 2 weeks after the start of agonist treatment, both being\r continued until adequate follicular development is achieved. For example,\r following two weeks of treatment with an agonist, 150\u2011225 IU\r follitropin alfa are administered for the first 7 days. The dose is then\r adjusted according to the ovarian response.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5074ae15-86e7-4348-be64-59be7d33f6ef","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Overall experience with\r IVF indicates that in general the treatment success rate remains stable during\r the first four attempts and gradually declines thereafter.<\/span><\/p>","ID":"c964ffbd-d5e4-4e7e-b8a9-cb18175532a1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Overall experience with\r IVF indicates that in general the treatment success rate remains stable during\r the first four attempts and gradually declines thereafter.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"835e3db1-b16f-43ca-90c6-531091d16dc5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Women with\r anovulation resulting from severe LH and FSH deficiency<\/span><\/u><\/i><\/p>","ID":"f0ba508d-1bc5-48ce-9c26-9bc301398fd8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Women with\r anovulation resulting from severe LH and FSH deficiency","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In LH and FSH deficient\r women (hypogonadotropic hypogonadism), the objective of follitropin alfa\r therapy in association with lutropin alfa is to develop a single mature\r Graafian follicle from which the oocyte will be liberated after the\r administration of hCG. Follitropin alfa should be given as a course of daily\r injections simultaneously with lutropin alfa. Since these patients are\r amenorrhoeic and have low endogenous oestrogen secretion, treatment can\r commence at any time.<\/span><\/p>","ID":"860123e1-4016-4cfe-b176-e4031702385d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In LH and FSH deficient\r women (hypogonadotropic hypogonadism), the objective of follitropin alfa\r therapy in association with lutropin alfa is to develop a single mature\r Graafian follicle from which the oocyte will be liberated after the\r administration of hCG. Follitropin alfa should be given as a course of daily\r injections simultaneously with lutropin alfa. Since these patients are\r amenorrhoeic and have low endogenous oestrogen secretion, treatment can\r commence at any time.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"238ea969-0c04-4768-9a6f-c2bd6731cd22","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A recommended regimen\r commences at 75 IU of lutropin alfa daily with 75\u2011150 IU FSH.\r Treatment should be tailored to the individual patient\u2019s response as assessed\r by measuring follicle size by ultrasound and oestrogen response.<\/span><\/p>","ID":"1a8a249d-0a9a-4aa5-930e-7ef3b9b0795a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A recommended regimen\r commences at 75 IU of lutropin alfa daily with 75\u2011150 IU FSH.\r Treatment should be tailored to the individual patient\u2019s response as assessed\r by measuring follicle size by ultrasound and oestrogen response.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1e5ab4c9-032c-4b5d-833c-7c78a2d23e51","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If an FSH dose increase\r is deemed appropriate, dose adaptation should preferably be after 7\u201114 day\r intervals and preferably by 37.5\u201175 IU increments. It may be\r acceptable to extend the duration of stimulation in any one cycle to up to\r 5 weeks.<\/span><\/p>","ID":"5a74a6bf-7b27-447f-b867-6d5f4914adbc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"If an FSH dose increase\r is deemed appropriate, dose adaptation should preferably be after 7\u201114 day\r intervals and preferably by 37.5\u201175 IU increments. It may be\r acceptable to extend the duration of stimulation in any one cycle to up to\r 5 weeks.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b8c11b60-6c26-4684-8b48-df48810a1498","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">When an optimal\r response is obtained, a single injection of 250 micrograms r\u2011hCG or\r 5,000 IU up to 10,000 IU hCG should be administered 24\u201148 hours\r after the last follitropin alfa and lutropin alfa injections. The patient is\r recommended to have coitus on the day of, and on the day following, hCG\r administration. Alternatively, IUI may be performed.<\/span><\/p>","ID":"4e2cfaba-b83e-49e8-b232-03cae3341833","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"When an optimal\r response is obtained, a single injection of 250 micrograms r\u2011hCG or\r 5,000 IU up to 10,000 IU hCG should be administered 24\u201148 hours\r after the last follitropin alfa and lutropin alfa injections. The patient is\r recommended to have coitus on the day of, and on the day following, hCG\r administration. Alternatively, IUI may be performed.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c25f6529-20c8-4e43-ba15-be7178899ad8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Luteal phase support\r may be considered since lack of substances with luteotropic activity (LH\/hCG)\r after ovulation may lead to premature failure of the corpus luteum.<\/span><\/p>","ID":"461762ec-6443-4b32-930f-56c0636e3ca7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Luteal phase support\r may be considered since lack of substances with luteotropic activity (LH\/hCG)\r after ovulation may lead to premature failure of the corpus luteum.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7a035b8a-fcaa-425a-8aa7-8a5ce1e5d39a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">If an excessive\r response is obtained, treatment should be stopped and hCG withheld. Treatment\r should recommence in the next cycle at a dose of FSH lower than that of the\r previous cycle.<\/span><\/p>","ID":"eae2420f-7721-43e6-9eb4-b9431df888bf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"If an excessive\r response is obtained, treatment should be stopped and hCG withheld. Treatment\r should recommence in the next cycle at a dose of FSH lower than that of the\r previous cycle.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cd257e4a-56d8-4eb0-86fc-4382ba765091","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Men with\r hypogonadotropic hypogonadism<\/span><\/u><\/i><\/p>","ID":"9526fd0f-3caa-448f-8c12-fce9fd59da30","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Men with\r hypogonadotropic hypogonadism","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Follitropin alfa should\r be given at a dose of 150 IU three times a week, concomitantly with hCG,\r for a minimum of 4 months. If after this period, the patient has not\r responded, the combination treatment may be continued; current clinical\r experience indicates that treatment for at least 18 months may be\r necessary to achieve spermatogenesis.<\/span><\/p>","ID":"14c1dd89-bc65-44c0-8f45-c2c02c9b344c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Follitropin alfa should\r be given at a dose of 150 IU three times a week, concomitantly with hCG,\r for a minimum of 4 months. If after this period, the patient has not\r responded, the combination treatment may be continued; current clinical\r experience indicates that treatment for at least 18 months may be\r necessary to achieve spermatogenesis.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"953acb43-dbd3-484b-b2ee-336db38a6f83","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Special population<\/span><\/u><\/i><\/p>","ID":"8fb8c290-f181-438a-974c-f16f98b1ae45","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Special population","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"d1015233-3f28-4214-9260-1edaa8c49f2e","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Elderly population<\/span><\/u><\/p>","ID":"bdf89740-bda3-4705-be66-13d225c1924b","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elderly population","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There is no relevant\r use of follitropin alfa in the elderly population. Safety and effectiveness of\r follitropin alfa in elderly patients have not been established.<\/span><\/p>","ID":"9d982a33-502c-442e-8b6a-6d64c20f3457","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no relevant\r use of follitropin alfa in the elderly population. Safety and effectiveness of\r follitropin alfa in elderly patients have not been established.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"37d15bf5-299d-46cb-bf9e-f045373a1c31","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Renal or hepatic\r impairment<\/span><\/u><\/p>","ID":"c8d91bb4-06f5-417b-a72b-92aa14bf71eb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal or hepatic\r impairment","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Safety, efficacy and\r pharmacokinetics of follitropin alfa in patients with renal or hepatic\r impairment have not been established.<\/span><\/p>","ID":"280b233c-b377-46dc-91e7-af8820c06a55","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Safety, efficacy and\r pharmacokinetics of follitropin alfa in patients with renal or hepatic\r impairment have not been established.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5def80e9-3524-4b07-876e-453d582e282f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:black\">Paediatric population<\/span><\/u><\/p>","ID":"014198f2-3c34-4928-bf03-2b0bc41ef4e4","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">There is no relevant use of follitropin alfa in the\r paediatric population.<\/span><\/p>","ID":"62b0e5eb-b39b-4c8a-ae72-f2da190e0170","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no relevant use of follitropin alfa in the\r paediatric population.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5055f703-89d5-43a1-a0ec-3d5d340e89ae","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Method of\r administration<\/span><\/u><\/i><\/p>","ID":"f15b8fa7-a809-43e0-9426-4a657101cf7a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Method of\r administration","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f12b0074-ecc0-4a1b-8a7a-4712cb5e47c9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is intended for\r subcutaneous use. The first injection should be performed under direct medical\r supervision. Self-administration should only be performed by patients who are\r well motivated, adequately trained and have access to expert advice.<\/span><\/p>","ID":"7acb11c0-1908-4fe4-9b51-115fcb956bab","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap is intended for\r subcutaneous use. The first injection should be performed under direct medical\r supervision. Self-administration should only be performed by patients who are\r well motivated, adequately trained and have access to expert advice.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"abe7663a-95b3-47af-a156-fe44de367e43","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">As the multidose\r cartridge is intended for several injections, clear instructions should be\r provided to the patients to avoid misuse of the medicine.<\/span><\/p>","ID":"abdb306a-c906-45f1-96d5-a9af573c5526","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As the multidose\r cartridge is intended for several injections, clear instructions should be\r provided to the patients to avoid misuse of the medicine.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f7e497ec-6a4b-430c-8e32-64042dab9e90","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The Ovaleap cartridge\r is designed for use in conjunction with the Ovaleap Pen only, which is\r separately available. For instructions on the administration with the<a name=\"OLE_LINK3\"> Ovaleap Pen<\/a>, see section 6.6.<\/span><\/p>","ID":"1ade226a-3d49-4d87-a7c7-945636f2e8b5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The Ovaleap cartridge\r is designed for use in conjunction with the Ovaleap Pen only, which is\r separately available. For instructions on the administration with the Ovaleap Pen, see section 6.6.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9ff40f8c-a61f-4562-874a-5611cfa3481f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p>","ID":"0cac7bbe-bc80-4a22-bdd6-90b7a8ef2881","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e3d7d52f-f859-4eea-99ef-51a28aacba95","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        Hypersensitivity to the active\r substance follitropin alfa, FSH or to any of the excipients<\/span><span lang=\"EN-GB\" style=\"color:black\">listed in section 6.1;<\/span><\/p>","ID":"4d44f8b2-1ada-44bb-b4c1-1b6de994141e","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        Hypersensitivity to the active\r substance follitropin alfa, FSH or to any of the excipientslisted in section 6.1;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        tumours of the hypothalamus or\r pituitary gland;<\/span><\/p>","ID":"4e52bad7-2a1f-4a0a-89c8-d49139f50f49","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        tumours of the hypothalamus or\r pituitary gland;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        ovarian enlargement or ovarian cyst not\r due to polycystic ovarian syndrome;<\/span><\/p>","ID":"a0e646dd-3c11-4693-957a-fa6f841f75ba","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        ovarian enlargement or ovarian cyst not\r due to polycystic ovarian syndrome;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        gynaecological haemorrhages of unknown\r aetiology;<\/span><\/p>","ID":"147aed33-b998-4617-92f0-ed61259f2f32","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        gynaecological haemorrhages of unknown\r aetiology;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        ovarian, uterine or mammary carcinoma.<\/span><\/p>","ID":"d3051f0d-1c40-47ee-8a39-f8109cfe007a","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        ovarian, uterine or mammary carcinoma.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p>","ID":"03a7d794-9d87-47b1-bc15-17f1bdb36420","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap must not be used when an effective\r response cannot be obtained, such as:<\/span><\/p>","ID":"1c1cce1a-4b53-458d-923f-369c85365bc6","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap must not be used when an effective\r response cannot be obtained, such as:","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        primary ovarian failure;<\/span><\/p>","ID":"895abd48-d227-4dc0-abc4-a37acfee5329","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        primary ovarian failure;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        malformations of sexual organs\r incompatible with pregnancy;<\/span><\/p>","ID":"7845a73d-66f5-43e4-a9dd-e5aa91c72025","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        malformations of sexual organs\r incompatible with pregnancy;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        fibroid tumours of the uterus incompatible\r with pregnancy;<\/span><\/p>","ID":"6e45ff37-706d-450f-9ec0-f1bb239c3ed9","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        fibroid tumours of the uterus incompatible\r with pregnancy;","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:black\">\u2022        primary testicular insufficiency.<\/span><\/p>","ID":"092f78c5-cf3f-40be-8147-9437e18a1481","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u2022        primary testicular insufficiency.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1ef1c14d-b7c5-4be3-90c3-5cd82c16384f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.4     Special warnings and precautions for use<\/span><\/b><\/p>","ID":"eb461f28-6236-407f-b281-593410271dc4","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions for use","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p>","ID":"026f4459-c25c-436f-a07b-c0c3e9776abd","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/i><\/p>","ID":"a1a9dca8-8bf0-4cc5-b6d2-076f52e8bffe","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Traceability","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\r biological medicinal products, the trade name and batch number of the\r administered medicinal product should be clearly recorded in the patient file.<\/span><\/p>","ID":"733cd133-1a5b-47bb-b4ed-23a93c08d954","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In order to improve the traceability of\r biological medicinal products, the trade name and batch number of the\r administered medicinal product should be clearly recorded in the patient file.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"26e47123-4d2c-489f-9fe9-622f109779f0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">General<\/span><\/u><\/i><\/p>","ID":"77231709-e072-4e7f-a634-aca9bbf4adcf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"General","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Follitropin alfa is a\r potent gonadotropic substance capable of causing mild to severe adverse\r reactions and should only be used by physicians who are thoroughly familiar\r with infertility problems and their management.<\/span><\/p>","ID":"29c85a4f-6dd1-4ee9-89b3-4e4b1cbe0e48","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Follitropin alfa is a\r potent gonadotropic substance capable of causing mild to severe adverse\r reactions and should only be used by physicians who are thoroughly familiar\r with infertility problems and their management.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e1018f77-9604-46e9-8d1f-0fa0097594fd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Gonadotropin therapy\r requires a certain time commitment by physicians and supportive health\r professionals, as well as the availability of appropriate monitoring\r facilities. In women, safe and effective use of follitropin alfa calls for\r monitoring of ovarian response with ultrasound, alone or preferably in\r combination with measurement of serum oestradiol levels, on a regular basis.\r There may be a degree of interpatient variability in response to FSH\r administration, with a poor response to FSH in some patients and exaggerated\r response in others. The lowest effective dose in relation to the treatment\r objective should be used in both men and women.<\/span><\/p>","ID":"d4b83322-30b8-4ab4-8447-0758ea28fccf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Gonadotropin therapy\r requires a certain time commitment by physicians and supportive health\r professionals, as well as the availability of appropriate monitoring\r facilities. In women, safe and effective use of follitropin alfa calls for\r monitoring of ovarian response with ultrasound, alone or preferably in\r combination with measurement of serum oestradiol levels, on a regular basis.\r There may be a degree of interpatient variability in response to FSH\r administration, with a poor response to FSH in some patients and exaggerated\r response in others. The lowest effective dose in relation to the treatment\r objective should be used in both men and women.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9c8975a8-b148-4c42-9bd3-70017a8a53bd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Porphyria<\/span><\/u><\/i><\/p>","ID":"e0749ad7-d47c-4ec4-aeb9-334626b9393c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Porphyria","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Patients with porphyria or a family history of porphyria\r should be closely monitored during treatment with follitropin alfa.\r Deterioration or a first appearance of this condition may require cessation of\r treatment.<\/span><\/p>","ID":"a3e28117-323c-4a49-9239-fdb1d6876f25","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients with porphyria or a family history of porphyria\r should be closely monitored during treatment with follitropin alfa.\r Deterioration or a first appearance of this condition may require cessation of\r treatment.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p>","ID":"c263d687-9200-4503-9e1b-064c9516f3de","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Treatment in\r women<\/span><\/u><\/i><\/p>","ID":"d62f0f27-5fc9-4f19-bf74-39226700418f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Treatment in\r women","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Before starting\r treatment, the couple\u2019s infertility should be assessed as appropriate and\r putative contraindications for pregnancy evaluated. In particular, patients\r should be evaluated for hypothyroidism, adrenocortical deficiency,\r hyperprolactinemia and appropriate specific treatment given.<\/span><\/p>","ID":"ce072b6b-a21a-4089-b47b-4ad48ab546d2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Before starting\r treatment, the couple\u2019s infertility should be assessed as appropriate and\r putative contraindications for pregnancy evaluated. In particular, patients\r should be evaluated for hypothyroidism, adrenocortical deficiency,\r hyperprolactinemia and appropriate specific treatment given.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9feced6b-2130-4cb7-a479-cc48cae36464","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Patients undergoing\r stimulation of follicular growth, whether as treatment for anovulatory\r infertility or ART procedures, may experience ovarian enlargement or develop\r hyperstimulation. Adherence to recommended follitropin alfa dose and regimen of\r administration and careful monitoring of therapy will minimise the incidence of\r such events. For accurate interpretation of the indices of follicle development\r and maturation, the physician should be experienced in the interpretation of\r the relevant tests.<\/span><\/p>","ID":"d9cf061c-2362-49a5-ac02-c4f7644390ee","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients undergoing\r stimulation of follicular growth, whether as treatment for anovulatory\r infertility or ART procedures, may experience ovarian enlargement or develop\r hyperstimulation. Adherence to recommended follitropin alfa dose and regimen of\r administration and careful monitoring of therapy will minimise the incidence of\r such events. For accurate interpretation of the indices of follicle development\r and maturation, the physician should be experienced in the interpretation of\r the relevant tests.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7995a7d7-264a-4298-afdc-7ef02fa3426e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In clinical trials, an\r increase of the ovarian sensitivity to follitropin alfa was shown when\r administered with lutropin alfa. If an FSH dose increase is deemed appropriate,\r dose adaptation should preferably be at 7\u201114 day intervals and\r preferably with 37.5\u201175 IU increments.<\/span><\/p>","ID":"ef9f2402-83b0-40be-8ba0-8e472aabf2ff","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In clinical trials, an\r increase of the ovarian sensitivity to follitropin alfa was shown when\r administered with lutropin alfa. If an FSH dose increase is deemed appropriate,\r dose adaptation should preferably be at 7\u201114 day intervals and\r preferably with 37.5\u201175 IU increments.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f52c26ad-1408-473f-ab2d-ca6fab1ef7a1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">No direct comparison of\r follitropin alfa\/LH versus human menopausal gonadotropin (hMG) has been\r performed. Comparison with historical data suggests that the ovulation rate\r obtained with follitropin alfa\/LH is similar to that obtained with hMG.<\/span><\/p>","ID":"9860cabd-27ad-44bb-bffa-08440e3b9137","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No direct comparison of\r follitropin alfa\/LH versus human menopausal gonadotropin (hMG) has been\r performed. Comparison with historical data suggests that the ovulation rate\r obtained with follitropin alfa\/LH is similar to that obtained with hMG.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c4480e34-0e8c-4166-8f8d-998f83f70469","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Ovarian\r Hyperstimulation Syndrome (OHSS)<\/span><\/i><\/p>","ID":"7efb12fb-96c9-4643-a678-8f3381071107","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Ovarian\r Hyperstimulation Syndrome (OHSS)","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">A certain degree of\r ovarian enlargement is an expected effect of controlled ovarian stimulation. It\r is more commonly seen in women with polycystic ovarian syndrome and usually\r regresses without treatment.<\/span><\/p>","ID":"9e939608-453b-44a2-b3ef-a6f36a60e01d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A certain degree of\r ovarian enlargement is an expected effect of controlled ovarian stimulation. It\r is more commonly seen in women with polycystic ovarian syndrome and usually\r regresses without treatment.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1d42e66c-70d9-4f46-a1c3-5a3facaec028","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In distinction to\r uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself\r with  increasing degrees of severity. It comprises marked ovarian enlargement,\r high serum sex steroids and an increase in vascular permeability which can\r result in an accumulation of fluid in the peritoneal, pleural and, rarely, in\r the pericardial cavities.<\/span><\/p>","ID":"26dc2cfa-676f-4099-806e-d3d6e2172c88","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In distinction to\r uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself\r with  increasing degrees of severity. It comprises marked ovarian enlargement,\r high serum sex steroids and an increase in vascular permeability which can\r result in an accumulation of fluid in the peritoneal, pleural and, rarely, in\r the pericardial cavities.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2e257b8c-3c81-472a-8424-e02e1cfde0a8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The following\r symptomatology may be observed in severe cases of OHSS: abdominal pain,\r abdominal distension, severe ovarian enlargement, weight gain, dyspnoea,\r oliguria and gastrointestinal symptoms including nausea, vomiting and\r diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration,\r electrolyte imbalances, ascites, haemoperitoneum, pleural effusions,\r hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be\r complicated by ovarian torsion or thromboembolic events such as pulmonary\r embolism, ischaemic stroke or myocardial infarction.<\/span><\/p>","ID":"f7903913-862f-4dac-9d58-a339ecb41b6c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following\r symptomatology may be observed in severe cases of OHSS: abdominal pain,\r abdominal distension, severe ovarian enlargement, weight gain, dyspnoea,\r oliguria and gastrointestinal symptoms including nausea, vomiting and\r diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration,\r electrolyte imbalances, ascites, haemoperitoneum, pleural effusions,\r hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be\r complicated by ovarian torsion or thromboembolic events such as pulmonary\r embolism, ischaemic stroke or myocardial infarction.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c6d1b0ce-5654-4f29-8a61-73dc3248c32e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Independent risk\r factors for developing OHSS include polycystic ovarian syndrome high absolute\r or rapidly rising serum oestradiol levels (e.g. &gt; 900 pg\/mL or\r &gt; 3,300 pmol\/L in anovulation; &gt; 3,000 pg\/mL or\r &gt; 11,000 pmol\/L in ART) and large number of developing ovarian\r follicles (e.g. &gt; 3 follicles of \u2265 14 mm in\r diameter in anovulation; \u2265 20 follicles of\r \u2265 12 mm in diameter in ART).<\/span><\/p>","ID":"3e690703-aae1-4dfd-9c4b-713d1a221971","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Independent risk\r factors for developing OHSS include polycystic ovarian syndrome high absolute\r or rapidly rising serum oestradiol levels (e.g. > 900 pg\/mL or\r > 3,300 pmol\/L in anovulation; > 3,000 pg\/mL or\r > 11,000 pmol\/L in ART) and large number of developing ovarian\r follicles (e.g. > 3 follicles of \u2265 14 mm in\r diameter in anovulation; \u2265 20 follicles of\r \u2265 12 mm in diameter in ART).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"61cdefb9-9b2b-42aa-a915-ddf2d00e789f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Adherence to\r recommended follitropin alfa dose and regimen of administration can minimise the\r risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of\r stimulation cycles by ultrasound scans as well as oestradiol measurements are\r recommended to early identify risk factors.<\/span><\/p>","ID":"e56d70f9-0eb1-4ffe-8f7b-cceb590153ff","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adherence to\r recommended follitropin alfa dose and regimen of administration can minimise the\r risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of\r stimulation cycles by ultrasound scans as well as oestradiol measurements are\r recommended to early identify risk factors.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"edc26ccb-f83f-4d0f-aafe-21d9e1fc43d4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There is evidence to\r suggest that hCG plays a key role in triggering OHSS and that the syndrome may\r be more severe and more protracted if pregnancy occurs. Therefore, if signs of\r ovarian hyperstimulation occur such as serum oestradiol level\r &gt; 5,500 pg\/mL or &gt; 20,200 pmol\/L and\/or\r \u2265 40 follicles in total, it is recommended that hCG be withheld\r and the patient be advised to refrain from coitus or to use barrier\r contraceptive methods for at least 4 days. OHSS may progress rapidly\r (within 24 hours) or over several days to become a serious medical event.\r It most often occurs after hormonal treatment has been discontinued and reaches\r its maximum at about 7 to 10 days following treatment. Therefore, patients\r should be followed for at least 2 weeks after hCG administration.<\/span><\/p>","ID":"7d25d80d-626d-4626-8d28-bb2e714dde47","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is evidence to\r suggest that hCG plays a key role in triggering OHSS and that the syndrome may\r be more severe and more protracted if pregnancy occurs. Therefore, if signs of\r ovarian hyperstimulation occur such as serum oestradiol level\r > 5,500 pg\/mL or > 20,200 pmol\/L and\/or\r \u2265 40 follicles in total, it is recommended that hCG be withheld\r and the patient be advised to refrain from coitus or to use barrier\r contraceptive methods for at least 4 days. OHSS may progress rapidly\r (within 24 hours) or over several days to become a serious medical event.\r It most often occurs after hormonal treatment has been discontinued and reaches\r its maximum at about 7 to 10 days following treatment. Therefore, patients\r should be followed for at least 2 weeks after hCG administration.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2e166246-a67a-4219-9d4b-bed14f06156b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In ART, aspiration of\r all follicles prior to ovulation may reduce the occurrence of hyperstimulation.<\/span><\/p>","ID":"9f2eef69-4d54-4279-ac50-8dd56bda94a0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In ART, aspiration of\r all follicles prior to ovulation may reduce the occurrence of hyperstimulation.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"de5b7059-1e23-467f-880c-343210d1c45e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Mild or moderate OHSS\r usually resolves spontaneously. If severe OHSS occurs, it is recommended that\r gonadotropin treatment be stopped if still ongoing and that the patient be\r hospitalised and appropriate therapy be started.<\/span><\/p>","ID":"e1d4c01e-9312-4154-9ab2-ca2fe035ad24","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Mild or moderate OHSS\r usually resolves spontaneously. If severe OHSS occurs, it is recommended that\r gonadotropin treatment be stopped if still ongoing and that the patient be\r hospitalised and appropriate therapy be started.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2137f8a6-98d2-4094-a53b-c6920b8fd007","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Multiple pregnancy<\/span><\/i><\/p>","ID":"5ff4cb1b-763c-4153-8a73-8b71bea5acc8","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Multiple pregnancy","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">In patients undergoing ovulation induction, the incidence\r of multiple pregnancy is increased compared with natural conception. The\r majority of multiple conceptions are twins. Multiple pregnancy, especially of\r high order, carries an increased risk of adverse maternal and perinatal\r outcomes.<\/span><\/p>","ID":"6e49eef2-54cc-4857-a35f-2bc7b4329102","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients undergoing ovulation induction, the incidence\r of multiple pregnancy is increased compared with natural conception. The\r majority of multiple conceptions are twins. Multiple pregnancy, especially of\r high order, carries an increased risk of adverse maternal and perinatal\r outcomes.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"632579fc-375e-44b2-b1ed-b60c9cce3987","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">To minimise the risk of\r multiple pregnancy, careful monitoring of ovarian response is recommended.<\/span><\/p>","ID":"03f676a6-efe0-454f-89e0-662ba640fa89","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"To minimise the risk of\r multiple pregnancy, careful monitoring of ovarian response is recommended.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a754c3b6-cd38-437a-80e5-9714be7fa54b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In patients undergoing\r ART procedures the risk of multiple pregnancy is related mainly to the number\r of embryos replaced, their quality and the patient age.<\/span><\/p>","ID":"8abae0d7-0ff9-413a-8efb-3b1946af4bc3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients undergoing\r ART procedures the risk of multiple pregnancy is related mainly to the number\r of embryos replaced, their quality and the patient age.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3300839d-3942-4507-8671-e12b3c5b012e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The patients should be\r advised of the potential risk of multiple births before starting treatment.<\/span><\/p>","ID":"1724a816-df2a-44fe-876a-8438c6451d44","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The patients should be\r advised of the potential risk of multiple births before starting treatment.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3f79f72b-7ef8-4f31-9487-304948abf106","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Pregnancy loss<\/span><\/i><\/p>","ID":"b228801a-9c2b-4d48-a11b-31d7b1d73cee","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Pregnancy loss","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The incidence of\r pregnancy loss by miscarriage or abortion is higher in patients undergoing\r stimulation of follicular growth for ovulation induction or ART than following\r natural conception.<\/span><\/p>","ID":"fd75e08a-29a7-40a4-94d2-a4d1c99f8582","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The incidence of\r pregnancy loss by miscarriage or abortion is higher in patients undergoing\r stimulation of follicular growth for ovulation induction or ART than following\r natural conception.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e8ac7bc0-f130-43af-a3d0-e32a4b0fcf0d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Ectopic pregnancy<\/span><\/i><\/p>","ID":"ef1cfd04-2178-4906-99d4-1466dbfc128e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Ectopic pregnancy","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Women with a history of\r tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained\r by spontaneous conception or with fertility treatments. The prevalence of\r ectopic pregnancy after ART, was reported to be higher than in the general\r population.<\/span><\/p>","ID":"fe3a11dc-33e1-464e-be62-5e5374188ee0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Women with a history of\r tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained\r by spontaneous conception or with fertility treatments. The prevalence of\r ectopic pregnancy after ART, was reported to be higher than in the general\r population.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"afce3372-f317-4b14-9b0e-fd16192d78de","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Reproductive system\r neoplasms<\/span><\/i><\/p>","ID":"3712b416-8074-4677-bf12-4b0ca6410983","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Reproductive system\r neoplasms","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There have been reports\r of ovarian and other reproductive system neoplasms, both benign and malignant,\r in women who have undergone multiple treatment regimens for infertility\r treatment. It is not yet established whether or not treatment with\r gonadotropins increases the risk of these tumours in infertile women.<\/span><\/p>","ID":"17d00b12-a890-4cd2-b37b-cb214af6e69a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There have been reports\r of ovarian and other reproductive system neoplasms, both benign and malignant,\r in women who have undergone multiple treatment regimens for infertility\r treatment. It is not yet established whether or not treatment with\r gonadotropins increases the risk of these tumours in infertile women.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3d9d9cf5-9676-4424-86fa-b26c58706b5a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Congenital\r malformation<\/span><\/i><\/p>","ID":"a981a739-3888-4ff0-95dc-e620c8a05dc6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Congenital\r malformation","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The prevalence of\r congenital malformations after ART may be slightly higher than after\r spontaneous conceptions. This is thought to be due to differences in parental\r characteristics (e.g. maternal age, sperm characteristics) and multiple\r pregnancies.<\/span><\/p>","ID":"f2bb3164-9a17-4f05-b4e6-5f3bea57514d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The prevalence of\r congenital malformations after ART may be slightly higher than after\r spontaneous conceptions. This is thought to be due to differences in parental\r characteristics (e.g. maternal age, sperm characteristics) and multiple\r pregnancies.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"184b401c-8d2c-40fe-9a7f-17e59e8710b3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"color:black\">Thromboembolic\r events<\/span><\/i><\/p>","ID":"8161c011-e60f-4dd7-8e82-0b06d71bf030","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Thromboembolic\r events","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In women with recent or\r ongoing thromboembolic disease or women with generally recognised risk factors\r for thromboembolic events, such as personal or family history, treatment with\r gonadotropins may further increase the risk for aggravation or occurrence of\r such events. In these women, the benefits of gonadotropin administration need\r to be weighed against the risks. It should be noted however that pregnancy\r itself as well as OHSS also carry an increased risk of thromboembolic events.<\/span><\/p>","ID":"8ad64778-8f6f-41f6-bd72-1a3f0a689e11","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In women with recent or\r ongoing thromboembolic disease or women with generally recognised risk factors\r for thromboembolic events, such as personal or family history, treatment with\r gonadotropins may further increase the risk for aggravation or occurrence of\r such events. In these women, the benefits of gonadotropin administration need\r to be weighed against the risks. It should be noted however that pregnancy\r itself as well as OHSS also carry an increased risk of thromboembolic events.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"7f35fa8d-d5e5-4047-b445-b21aac750045","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"f12d34cd-c5b0-4a53-8a91-b3876bcdd091","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"7f35fa8d-d5e5-4047-b445-b21aac750045"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"fa036dee-7b78-4f13-b24a-b71d781cc588","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5d8e252f-60eb-4988-a601-6c5e53bdc690","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Treatment in men<\/span><\/u><\/i><\/p>","ID":"4f2c5ae2-6a5d-4861-8e50-ab98c2cc2368","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Treatment in men","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Elevated endogenous FSH\r levels are indicative of primary testicular failure. Such patients are\r unresponsive to follitropin alfa\/hCG therapy. Follitropin alfa should not be\r used when an effective response cannot be obtained.<\/span><\/p>","ID":"96fe96ca-50fe-47e9-b733-ed83910d4c6d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Elevated endogenous FSH\r levels are indicative of primary testicular failure. Such patients are\r unresponsive to follitropin alfa\/hCG therapy. Follitropin alfa should not be\r used when an effective response cannot be obtained.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d7addf11-462e-4574-a0b9-30ba59558d00","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Semen analysis is\r recommended 4 to 6 months after the beginning of treatment as part of the\r assessment of the response.<\/span><\/p>","ID":"aff2ea83-a295-4440-89bd-8400af43596a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Semen analysis is\r recommended 4 to 6 months after the beginning of treatment as part of the\r assessment of the response.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a6ebbf96-b977-4221-acff-07f8c367d6c8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Benzalkonium\r chloride content<\/span><\/u><\/i><\/p>","ID":"6ae79689-8ce8-4eb5-9954-6386a59b8da9","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Benzalkonium\r chloride content","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap contains 0.02 mg\/mL of benzalkonium chloride<\/span><\/p>","ID":"f6ac31cb-ef60-4cc4-a552-e8679abed6c1","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap contains 0.02 mg\/mL of benzalkonium chloride","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"3343001a-a20b-4a38-8ce3-59d267ef90c5","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Benzyl\r alcohol content<\/span><\/u><\/i><\/p>","ID":"e0dd5f77-8588-4ea3-a141-0550798fd0ff","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Benzyl\r alcohol content","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ovaleap\r contains <\/span><span lang=\"EN-GB\">10.0 mg per mL benzyl alcohol<\/span><\/p>","ID":"0e43ea96-7639-40fd-8eca-5d468ad3404e","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap\r contains 10.0 mg per mL benzyl alcohol","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Benzyl\r alcohol may cause allergic reactions.<\/span><\/u><\/p>","ID":"d8c5fc59-b1b0-4590-8d42-eef136242662","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Benzyl\r alcohol may cause allergic reactions.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">High volumes\r should be used with caution and only if necessary, especially in subjects with\r liver or kidney impairment as well as in pregnant women or while\r breast-feeding, because of the risk of accumulation and toxicity (metabolic\r acidosis).<\/span><\/p>","ID":"52b35724-7915-46a3-b359-ca8f6d8eb641","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"High volumes\r should be used with caution and only if necessary, especially in subjects with\r liver or kidney impairment as well as in pregnant women or while\r breast-feeding, because of the risk of accumulation and toxicity (metabolic\r acidosis).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"3f2e3147-4b9a-4876-a8d8-5616bb99bf29","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Sodium\r content<\/span><\/u><\/i><\/p>","ID":"a7ae3c4c-8be6-43ea-9cd0-54180e13976c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Sodium\r content","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap contains less than 1 mmol sodium (23 mg)\r per dose, that is to say essentially \u201csodium\u00adfree\u201d.<\/span><\/p>","ID":"1b9b4ec5-562b-4049-9529-f4e236faade2","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap contains less than 1 mmol sodium (23 mg)\r per dose, that is to say essentially \u201csodium\u00adfree\u201d.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cee160a1-6637-45b6-afde-62e486e61039","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">4.5     Interaction with other medicinal products\r and other forms of interaction<\/span><\/b><\/p>","ID":"6179bbf1-4331-41a9-93c8-af926ff1cb07","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal products\r and other forms of interaction","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"b497df14-f178-49c8-a101-ba66d6138b1d","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Concomitant use of follitropin alfa with other medicinal\r products used to stimulate ovulation (e.g. hCG, clomifene citrate) may\r potentiate the follicular response, whereas concurrent use of a GnRH agonist or\r antagonist to induce pituitary desensitisation may increase the dose of\r follitropin alfa needed to elicit an adequate ovarian response. No other\r clinically significant medicinal product interaction has been reported during\r follitropin alfa therapy.<\/span><\/p>","ID":"26ee00ca-c0c1-438a-8dd1-99001ed53dfc","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Concomitant use of follitropin alfa with other medicinal\r products used to stimulate ovulation (e.g. hCG, clomifene citrate) may\r potentiate the follicular response, whereas concurrent use of a GnRH agonist or\r antagonist to induce pituitary desensitisation may increase the dose of\r follitropin alfa needed to elicit an adequate ovarian response. No other\r clinically significant medicinal product interaction has been reported during\r follitropin alfa therapy.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bf64388a-65d6-4ab4-b091-86531ca0e0b9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p>","ID":"8525371a-3b52-4c99-a086-cd5d20477fb2","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a09e13ce-ca10-43af-903e-4aaeb986d9be","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Pregnancy<\/span><\/u><\/i><\/p>","ID":"16072ecf-927a-4af5-9c1e-1a2ed8fb48a6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Pregnancy","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5a8e2519-92b9-4693-a0c1-8e8fecebefef","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">There is no indication\r for use of Ovaleap during pregnancy. Data on a limited number of exposed\r pregnancies (less than 300 pregnancy outcomes) indicate no malformative or\r foeto\/neonatal toxicity of follitropin alfa.<\/span><\/p>","ID":"fdfdd79b-59e5-4b84-9d4c-90c0183e6b57","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no indication\r for use of Ovaleap during pregnancy. Data on a limited number of exposed\r pregnancies (less than 300 pregnancy outcomes) indicate no malformative or\r foeto\/neonatal toxicity of follitropin alfa.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"52b98fc0-b8d9-465a-a176-1673c608dd2c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">No teratogenic effect\r has been observed in animal studies (see section 5.3). In case of exposure\r during pregnancy, clinical data are not sufficient to exclude a teratogenic\r effect of follitropin alfa.<\/span><\/p>","ID":"70225548-5d3f-4159-8e00-8074dae8f8a0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No teratogenic effect\r has been observed in animal studies (see section 5.3). In case of exposure\r during pregnancy, clinical data are not sufficient to exclude a teratogenic\r effect of follitropin alfa.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6b24db6e-5eac-418f-be6d-e838f88bb24b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Breast\u2011feeding<\/span><\/u><\/i><\/p>","ID":"3a73c6de-f951-4e5f-a3c1-eb6899f90ec8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Breast\u2011feeding","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p>","ID":"1e1e5ceb-e1de-4113-ad93-1120ef528ec6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is not\r indicated during breast\u2011feeding.<\/span><\/p>","ID":"91f2b0a8-2027-4737-93c1-9d618b587a8b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap is not\r indicated during breast\u2011feeding.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"363fffa9-e9f3-4c04-b043-36bf2286ef61","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Fertility<\/span><\/u><\/i><\/p>","ID":"0ee9beb3-1c04-42b9-8bd5-2479bcb35afc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Fertility","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\"><\/span><\/u><\/p>","ID":"2c7376f4-a4af-4372-a516-a6615ebc0590","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is indicated\r for use in infertility (see section 4.1).<\/span><\/p>","ID":"2c0fa64e-8192-46fd-b976-d888d2ae496b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap is indicated\r for use in infertility (see section 4.1).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ac24268c-d2a4-4512-b592-b450e5657b8e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p>","ID":"9b6ddffa-70a2-4950-b91a-a7fb9ced9a53","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and use machines","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c26f8878-e841-4912-bf65-b604f39d135c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ovaleap has no or negligible influence on\r the ability to drive and use machines.<\/span><\/p>","ID":"65ab79cc-eb43-4eb2-979b-4bc26a6ce694","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap has no or negligible influence on\r the ability to drive and use machines.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"02673ec1-6363-45dc-9196-e945cde42ac2","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"4f5d81c0-29c8-43f7-b9f5-c52c6edcdd39","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"02673ec1-6363-45dc-9196-e945cde42ac2"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"52a334d2-a9ce-4dfc-b8f3-27f86a4cbc01","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"6d01b858-83f2-4051-9cd6-d1022144ab12","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/b><\/p>","ID":"d2979659-7f5c-4d5e-a62f-ccaf800e63ad","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p>","ID":"bd6103bf-b900-48ea-bf99-87da20e1a7dc","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Summary of the\r safety profile<\/span><\/u><\/i><\/p>","ID":"4e7475ed-8ede-48e6-9094-b008fba288ac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Summary of the\r safety profile","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"8fce4de8-9a3c-4794-9916-d8d6e4355b30","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The most commonly\r reported adverse reactions are headache, ovarian cysts and local injection site\r reactions (e.g. pain, erythema, haematoma, swelling and\/or irritation at the\r site of injection).<\/span><\/p>","ID":"acd87f41-0957-4f2f-a39a-5846e6deacb6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The most commonly\r reported adverse reactions are headache, ovarian cysts and local injection site\r reactions (e.g. pain, erythema, haematoma, swelling and\/or irritation at the\r site of injection).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b5d47d69-e8a3-43e9-ae6f-1c3631f5f883","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Mild or moderate OHSS\r has been commonly reported and should be considered as an intrinsic risk of the\r stimulation procedure. Severe OHSS is uncommon (see section 4.4).<\/span><\/p>","ID":"00034efb-b319-4f06-8c88-c69ef80c726b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Mild or moderate OHSS\r has been commonly reported and should be considered as an intrinsic risk of the\r stimulation procedure. Severe OHSS is uncommon (see section 4.4).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0610b12b-2c91-47e7-8077-89ceedb316bc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Thromboembolism may\r occur very rarely (see section 4.4).<\/span><\/p>","ID":"a9ef6de4-dfe6-4578-bb61-64742a5c7833","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Thromboembolism may\r occur very rarely (see section 4.4).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2294d3ad-989d-4cda-b765-c94950d200e2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Tabulated list of\r adverse reactions<\/span><\/u><\/i><\/p>","ID":"c3f5eead-2a8a-4527-a398-8a5e95a05b3f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Tabulated list of\r adverse reactions","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">The adverse reactions are ranked under heading of frequency using\r the following convention: very<\/span><\/p>","ID":"274f6af2-a3ca-4a44-ade5-f243ca7842e5","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The adverse reactions are ranked under heading of frequency using\r the following convention: very","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">common (\u22651\/10), common (\u22651\/100 to &lt;1\/10), uncommon (\u22651\/1,000\r to &lt;1\/100), rare (\u22651\/10,000 to<\/span><\/p>","ID":"a4971534-922f-4260-904e-acecb1f43577","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"common (\u22651\/10), common (\u22651\/100 to <1\/10), uncommon (\u22651\/1,000\r to <1\/100), rare (\u22651\/10,000 to","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">&lt;1\/1,000), very rare (&lt;1\/10,000) and not known (cannot be\r estimated from the available data). Within<\/span><\/p>","ID":"2eacbe29-8f24-4864-9c62-7cfe2a238b35","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"<1\/1,000), very rare (<1\/10,000) and not known (cannot be\r estimated from the available data). Within","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><span lang=\"EN-GB\">each frequency grouping, adverse reactions are presented in order of\r decreasing seriousness.<\/span><\/p>","ID":"5839c639-87d3-474d-bc81-ebd7f3e2dbbe","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"each frequency grouping, adverse reactions are presented in order of\r decreasing seriousness.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9f2f9f49-3be7-404d-bd46-92e27eca3737","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Treatment in women<\/span><\/i><\/p>","ID":"f15a9062-6f4d-42dc-b0e5-70cda0526532","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Treatment in women","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"457bfb38-d73f-4f2c-b0bb-e2e624fa3946","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td colspan=\"3\" style=\"width:460.6pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\r   1: Adverse reactions in women<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">System\r   organ class<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Adverse\r   reaction<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Immune\r   system disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Mild to severe hypersensitivity reactions, including anaphylactic\r   reactions and shock<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Nervous\r   system disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Headache<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Vascular disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Thromboembolism (both in association with and separate\r   from OHSS)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Exacerbation or aggravation of asthma<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common:<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Abdominal pain, abdominal distension, abdominal\r   discomfort, nausea, vomiting, diarrhoea<\/span><\/p> <\/td> <\/tr> <tr> <td rowspan=\"4\" style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Reproductive system and breast disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Ovarian cysts<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Mild or moderate OHSS (including associated\r   symptomatology)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Severe OHSS (including associated symptomatology) (see\r   section 4.4)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Complication of severe OHSS<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">General\r   disorders and administration site conditions<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Injection site reactions (e.g. pain, erythema, haematoma,\r   swelling and\/or irritation at the site of injection)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"1670bef9-c559-4b1e-8540-a2fa3ac39e3c","Styles":"border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"   Table\r   1: Adverse reactions in women     System\r   organ class   Frequency   Adverse\r   reaction     Immune\r   system disorders   Very rare   Mild to severe hypersensitivity reactions, including anaphylactic\r   reactions and shock     Nervous\r   system disorders   Very common   Headache     Vascular disorders   Very rare   Thromboembolism (both in association with and separate\r   from OHSS)     Respiratory, thoracic and mediastinal disorders   Very rare   Exacerbation or aggravation of asthma     Gastrointestinal disorders   Common:   Abdominal pain, abdominal distension, abdominal\r   discomfort, nausea, vomiting, diarrhoea     Reproductive system and breast disorders   Very common   Ovarian cysts     Common   Mild or moderate OHSS (including associated\r   symptomatology)     Uncommon   Severe OHSS (including associated symptomatology) (see\r   section 4.4)     Rare   Complication of severe OHSS     General\r   disorders and administration site conditions   Very common   Injection site reactions (e.g. pain, erythema, haematoma,\r   swelling and\/or irritation at the site of injection)   ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p>","ID":"315a3dbe-1b55-4400-888b-d612cfb9f819","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"e7dcc440-5a22-4fe0-bf15-2a8d3253aa76","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"7312e9d5-7c97-45ad-8c77-c59bc3a580f4","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"e7dcc440-5a22-4fe0-bf15-2a8d3253aa76"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"8d58cd45-fde4-4577-974b-3d7aa1e4015e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p>","ID":"c58c2dee-3e7b-42ec-b148-02342b623766","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><i><span lang=\"EN-GB\" style=\"color:black\">Treatment in men<\/span><\/i><\/p>","ID":"fcfcc89f-5640-467a-88ea-fbf40fb4b7d5","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Treatment in men","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-85.05pt\"><\/p>","ID":"325b029a-e0c9-4cca-bc0b-d2b3ab56835a","Styles":"margin-left:85.05pt;text-indent:-85.05pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td colspan=\"3\" style=\"width:460.6pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"614\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table\r   2: Adverse reactions in men<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">System\r   organ class<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency<\/span><\/b><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Adverse\r   reaction<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Immune\r   system disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Mild to severe hypersensitivity reactions, including\r   anaphylactic reactions and shock<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Respiratory, thoracic and mediastinal disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very rare<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Exacerbation or aggravation of asthma<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common:<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Acne<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Reproductive system and breast disorders<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Gynaecomastia, varicocele<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">General\r   disorders and administration site conditions<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Very common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Injection site reactions (e.g. pain, erythema, haematoma,\r   swelling and\/or irritation at the site of injection)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:153.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Investigations<\/span><\/i><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Common<\/span><\/p> <\/td> <td style=\"width:153.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Weight gain<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"2c481f0c-3751-43c5-8cd7-685b992bf167","Styles":"border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"   Table\r   2: Adverse reactions in men     System\r   organ class   Frequency   Adverse\r   reaction     Immune\r   system disorders   Very rare   Mild to severe hypersensitivity reactions, including\r   anaphylactic reactions and shock     Respiratory, thoracic and mediastinal disorders   Very rare   Exacerbation or aggravation of asthma     Skin and subcutaneous tissue disorders   Common:   Acne     Reproductive system and breast disorders   Common   Gynaecomastia, varicocele     General\r   disorders and administration site conditions   Very common   Injection site reactions (e.g. pain, erythema, haematoma,\r   swelling and\/or irritation at the site of injection)     Investigations   Common   Weight gain   ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"82efc434-3a57-4549-8717-c0bb4a6114f9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"557d6497-5331-4403-83b7-0c1484b55d23","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse reactions","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\r authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:lightgrey\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"e10011c5-7265-4ca3-8724-04b01f705c74","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions after\r authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"fc01e4d2-c13d-4672-aa6b-3a01cf4a20f2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"beb7e647-ce91-4a97-a6e9-eaab7d44245b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p>","ID":"097cc068-e229-4135-81de-c61e29ea292e","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e38ea149-5078-4982-8a7d-5a166775668c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The effects of an\r overdose of follitropin alfa are unknown, nevertheless, there is a possibility\r that OHSS may occur (see section 4.4).<\/span><\/p>","ID":"a46ede78-a0e1-4328-ab6e-77c2c60b9003","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The effects of an\r overdose of follitropin alfa are unknown, nevertheless, there is a possibility\r that OHSS may occur (see section 4.4).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ab61658a-3709-47ca-b354-176c61978812","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e5613aa0-186b-496a-98d7-3a335410209b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p>","ID":"ceeaac96-4df6-4cb2-92db-84585197bf3a","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"6a978e6a-4659-404a-ae33-67cb004a6734","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/b><\/p>","ID":"0fe3ad8e-a02b-4b76-be00-7307e1b11923","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p>","ID":"76b88d82-5b39-4f53-a9b0-4b5620ac7ede","Styles":"margin-right:-.1pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pharmacotherapeutic\r group: Sex hormones and modulators of the genital systems, gonadotropins, ATC\r code: G03GA05.<\/span><\/p>","ID":"831b334b-5793-4335-98c5-1d4981bedc51","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic\r group: Sex hormones and modulators of the genital systems, gonadotropins, ATC\r code: G03GA05.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4019963f-87b6-40c0-8af5-b2010291bc4c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap<\/span><span lang=\"EN-GB\" style=\"color:black\"> is a biosimilar medicinal product. Detailed\r information is available on the website of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:black;\r text-decoration:none\">http:\/\/www.ema.europa.eu<\/span><\/a><span style=\"color:black\">.<\/span><\/span><\/p>","ID":"8af1946b-b717-4713-b55f-c898cc207fa0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap is a biosimilar medicinal product. Detailed\r information is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b68f7cfb-80d6-4a9f-8b88-f74a6c717a07","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Pharmacodynamic\r effects<\/span><\/u><\/i><\/p>","ID":"541fcd47-7d0e-455e-9e07-3a4e81c98021","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Pharmacodynamic\r effects","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c964eb7d-0dda-417a-83e7-c1aed4357052","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In women, the most important\r effect resulting from parenteral administration of FSH is the development of\r mature Graafian follicles. In women with anovulation, the object of follitropin\r alfatherapy is to develop a single\r mature Graafian follicle from which the ovum will be liberated after the\r administration of hCG.<\/span><\/p>","ID":"be9070f4-81d2-491a-9a3b-e022014fd65e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In women, the most important\r effect resulting from parenteral administration of FSH is the development of\r mature Graafian follicles. In women with anovulation, the object of follitropin\r alfatherapy is to develop a single\r mature Graafian follicle from which the ovum will be liberated after the\r administration of hCG.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"23e83f3b-7a71-46c0-9abf-c46f34130b41","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Clinical efficacy\r and safety in women<\/span><\/u><\/i><\/p>","ID":"847627c9-7b70-4462-9f7f-4e763c2b3d33","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Clinical efficacy\r and safety in women","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c1b742dd-5e0a-4252-8ec5-a4dad13aad81","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In clinical trials,\r patients with severe FSH and LH deficiency were defined by an endogenous serum\r LH level &lt; 1.2 IU\/L as measured in a central laboratory. However,\r it should be taken into account that there are variations between LH\r measurements performed in different laboratories.<\/span><\/p>","ID":"5e6a760c-2293-4c37-891d-6ee2c0177785","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In clinical trials,\r patients with severe FSH and LH deficiency were defined by an endogenous serum\r LH level < 1.2 IU\/L as measured in a central laboratory. However,\r it should be taken into account that there are variations between LH\r measurements performed in different laboratories.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5b9c8b39-ec86-4a17-8bea-42c5084ec8f8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In clinical studies\r comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 3 below)\r and in ovulation induction, follitropin alfa was more potent than urinary FSH\r in terms of a lower total dose and a shorter treatment period needed to trigger\r follicular maturation.<\/span><\/p>","ID":"0c8a0c5a-af99-43f0-9a58-89fd5e34f1b3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In clinical studies\r comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 3 below)\r and in ovulation induction, follitropin alfa was more potent than urinary FSH\r in terms of a lower total dose and a shorter treatment period needed to trigger\r follicular maturation.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f4b7f5f3-9df9-41b6-840e-700b6065db8c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In ART, follitropin\r alfa at a lower total dose and shorter treatment period than urinary FSH,\r resulted in a higher number of oocytes retrieved when compared to urinary FSH.<\/span><\/p>","ID":"02cefd86-c505-4666-bcb5-efa67db0f270","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In ART, follitropin\r alfa at a lower total dose and shorter treatment period than urinary FSH,\r resulted in a higher number of oocytes retrieved when compared to urinary FSH.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a42bff24-6de0-4735-9250-658349ba093c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Table 3: Results of\r study GF 8407 (randomised parallel group study comparing efficacy and safety of\r follitropin alfa with urinary FSH in ART)<\/span><\/p>","ID":"ec414647-690f-4cb2-9e2c-14c54a470bf1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table 3: Results of\r study GF 8407 (randomised parallel group study comparing efficacy and safety of\r follitropin alfa with urinary FSH in ART)","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:402.3pt;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"536\"> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:106.3pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">follitropin\r   alfa<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">(n = 130)<\/span><\/p> <\/td> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">urinary FSH<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">(n = 116)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Number of oocytes retrieved<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">11.0 \u00b1 5.9<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">8.8 \u00b1 4.8<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Days of FSH stimulation required<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">11.7 \u00b1 1.9<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">14.5 \u00b1 3.3<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Total dose of FSH required (number of FSH 75 IU\r   ampoules)<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">27.6 \u00b1 10.2<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">40.7 \u00b1 13.6<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:182.6pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"243\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Need to increase the dose (%)<\/span><\/p> <\/td> <td style=\"width:106.3pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">56.2<\/span><\/p> <\/td> <td style=\"width:113.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:black\">85.3<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"d213b24c-4472-4ac5-af6f-1614f2516c45","Styles":"width:402.3pt;margin-left:5.4pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"      follitropin\r   alfa (n = 130)   urinary FSH (n = 116)     Number of oocytes retrieved   11.0 \u00b1 5.9   8.8 \u00b1 4.8     Days of FSH stimulation required   11.7 \u00b1 1.9   14.5 \u00b1 3.3     Total dose of FSH required (number of FSH 75 IU\r   ampoules)   27.6 \u00b1 10.2   40.7 \u00b1 13.6     Need to increase the dose (%)   56.2   85.3   ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9009d4ac-581f-4cc9-b743-990a7f853445","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Differences between the\r 2 groups were statistically significant (p &lt; 0.05) for all\r criteria listed.<\/span><\/p>","ID":"5875ec96-c1f1-470f-bd57-0f1772d3acab","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Differences between the\r 2 groups were statistically significant (p < 0.05) for all\r criteria listed.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ca3c6532-1363-417e-9ee4-9bd0ddb63535","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><i><u><span lang=\"EN-GB\" style=\"color:black\">Clinical efficacy\r and safety in men<\/span><\/u><\/i><\/p>","ID":"474dfcb7-cbe2-4032-9e45-d8eedf34007e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Clinical efficacy\r and safety in men","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e928e0ca-14d3-4994-b330-55cb6b3abf55","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In men deficient in\r FSH, follitropin alfa administered concomitantly with hCG for at least\r 4 months induces spermatogenesis.<\/span><\/p>","ID":"3c65d81e-1a68-454b-bbe5-350d81d1b429","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In men deficient in\r FSH, follitropin alfa administered concomitantly with hCG for at least\r 4 months induces spermatogenesis.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p>","ID":"6809609a-9185-455d-bc29-b68734d15b3a","Styles":"margin-right:-.1pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/b><\/p>","ID":"4c37b6f4-2374-4cb1-8b85-c58139394890","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><\/p>","ID":"f12da2be-22d4-4c68-b2ab-5cba796146e0","Styles":"margin-right:-.1pt;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Following intravenous administration,\r follitropin alfa is distributed to the extracellular fluid space with <\/span><span lang=\"EN-GB\" style=\"color:black\">an initial half-life of around 2 hours and\r eliminated from the body with a terminal half-life of about one day. The steady\r state volume of distribution and total clearance are 10 L and 0.6 L\/h,\r respectively. One\u2011eighth of the follitropin alfa dose is excreted in the\r urine.<\/span><\/p>","ID":"1292104e-e4bd-4866-a96f-11adbd3ecead","Styles":"margin-right:-.1pt;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following intravenous administration,\r follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and\r eliminated from the body with a terminal half-life of about one day. The steady\r state volume of distribution and total clearance are 10 L and 0.6 L\/h,\r respectively. One\u2011eighth of the follitropin alfa dose is excreted in the\r urine.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p>","ID":"c9f7a70a-d7a0-45e6-bc9b-65a8048d0a8b","Styles":"margin-right:-.1pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:black\">Following subcutaneous administration, the absolute\r bioavailability is about 70 %. Following repeated administration,\r follitropin alfa accumulates 3\u2011fold achieving a steady-state within 3\u20114 days.\r In women whose endogenous gonadotropin secretion is suppressed, follitropin\r alfa has nevertheless been shown to effectively stimulate follicular\r development and steroidogenesis, despite unmeasurable LH levels. <\/span><\/p>","ID":"d017e549-773b-4d67-a38d-486dc95244ef","Styles":"margin-right:-.1pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following subcutaneous administration, the absolute\r bioavailability is about 70 %. Following repeated administration,\r follitropin alfa accumulates 3\u2011fold achieving a steady-state within 3\u20114 days.\r In women whose endogenous gonadotropin secretion is suppressed, follitropin\r alfa has nevertheless been shown to effectively stimulate follicular\r development and steroidogenesis, despite unmeasurable LH levels. ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><\/p>","ID":"cf09d13a-7c86-41a4-aadc-8004fae8239c","Styles":"margin-right:-.1pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p>","ID":"d59a3ead-5500-4583-8ad9-e3efed6e7fd3","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3     Preclinical safety data","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"33e507f1-3ff0-4813-b122-280bd8ca6b26","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Non-clinical data reveal no special hazard for humans based\r on conventional studies of single and repeated dose toxicity and genotoxicity\r additional to that already stated in other sections of this SmPC.<\/span><\/p>","ID":"6882038b-8769-468d-9957-ea4be5b4db7c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-clinical data reveal no special hazard for humans based\r on conventional studies of single and repeated dose toxicity and genotoxicity\r additional to that already stated in other sections of this SmPC.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cc1c0741-979a-4400-ab92-2e343be41d01","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Impaired fertility has\r been reported in rats exposed to pharmacological doses of follitropin alfa\r (\u2265 40 IU\/kg\/day) for extended periods, through reduced\r fecundity.<\/span><\/p>","ID":"81eaf083-6358-4a04-ae8c-b2c84a1815f2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Impaired fertility has\r been reported in rats exposed to pharmacological doses of follitropin alfa\r (\u2265 40 IU\/kg\/day) for extended periods, through reduced\r fecundity.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"b851240b-5ac9-4cce-83d4-334d3bb5aec9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Given in high doses\r (\u2265 5 IU\/kg\/day) follitropin alfa caused a decrease in the\r number of viable foetuses without being a teratogen and dystocia similar to\r that observed with urinary Menopausal Gonadotropin (hMG). However, since Ovaleap\r is not indicated in pregnancy, these data are of limited clinical relevance.<\/span><\/p>","ID":"194c1277-bee7-4075-a80d-5ac59d4925e4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Given in high doses\r (\u2265 5 IU\/kg\/day) follitropin alfa caused a decrease in the\r number of viable foetuses without being a teratogen and dystocia similar to\r that observed with urinary Menopausal Gonadotropin (hMG). However, since Ovaleap\r is not indicated in pregnancy, these data are of limited clinical relevance.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f2fc9860-8502-4756-9693-49b2d56ab49c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e6813946-e0aa-4494-a52c-c2690de7c0bb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p>","ID":"5690b355-cc7d-47f9-88cc-85e863841258","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><\/p>","ID":"6171f339-be13-4e93-b70a-94955504d339","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p>","ID":"6573e5ae-63e1-45bd-abbe-8ca4125b2c5f","Styles":"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"01843587-a4ae-44bf-87fe-abb205a001f7","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Sodium dihydrogen\r phosphate dihydrate<\/span><\/p>","ID":"45c172d3-ce74-4a8f-ba3e-db6f18ffe389","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Sodium dihydrogen\r phosphate dihydrate","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Sodium hydroxide\r (2 M) (for pH adjustment)<\/span><\/p>","ID":"eac21f44-34c4-4645-8c33-18caa73731ab","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Sodium hydroxide\r (2 M) (for pH adjustment)","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Mannitol<\/span><\/p>","ID":"a10ecbe2-adc5-4909-b0c9-f2e1132a39ed","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Mannitol","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Methionine<\/span><\/p>","ID":"00f919ee-099d-4fb9-b6cf-a99a85666b60","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Methionine","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Polysorbate 20<\/span><\/p>","ID":"c68f80d6-5fe6-4c1a-932a-64fe036fff2e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Polysorbate 20","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Benzyl alcohol<\/span><\/p>","ID":"742115e4-a8e8-4558-a558-b5e85e85c6d1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Benzyl alcohol","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Benzalkonium chloride<\/span><\/p>","ID":"6dcd9fe7-13ff-4df9-b55d-02263cd388e1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Benzalkonium chloride","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Water for injections<\/span><\/p>","ID":"48f48a3e-8464-469f-a67d-a44d992ba881","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Water for injections","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"044b0d43-e877-4685-a447-95acc4939ee3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p>","ID":"0217a98d-08bb-40a5-9f93-536a84fdbc58","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4784e6f0-543f-47fd-ad88-6578892e16dc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">In the absence of\r compatibility studies, this medicinal product must not be mixed with other\r medicinal products.<\/span><\/p>","ID":"dad5ed31-8897-43bf-9c46-b2911322f93b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In the absence of\r compatibility studies, this medicinal product must not be mixed with other\r medicinal products.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f3d1a38e-7a72-460c-bc11-96a34e1b27d5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p>","ID":"3e637c25-ac92-4411-b7b2-719e037076c1","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"c5507c71-2c12-4e3c-a6f3-d6c3edbec5ee","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:red\">3<\/span><span lang=\"EN-GB\" style=\"color:black\"> years.<\/span><\/p>","ID":"4e4b5f3b-3965-4e75-bb9a-e9e0cd4b497f","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bbe6289e-1833-4757-abbd-135e96dd4de5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:black\">Shelf life<\/span><\/u><u><span lang=\"EN-GB\"> and storage conditions after first opening<\/span><\/u><\/p>","ID":"9a0c62fa-2c84-4edf-8cfb-f35ae43dc139","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Shelf life and storage conditions after first opening","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The cartridge in\u2011use\r in the pen may be stored for a maximum of 28 days. Do not store above\r 25 \u00b0C. The patient should write down in the patient diary provided with\r the Ovaleap Pen the date of first use.<\/span><\/p>","ID":"647d1671-f24e-437e-b207-df6864784f49","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The cartridge in\u2011use\r in the pen may be stored for a maximum of 28 days. Do not store above\r 25 \u00b0C. The patient should write down in the patient diary provided with\r the Ovaleap Pen the date of first use.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"aa1a813f-0289-4ecc-bcb0-8513c89f5713","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The pen cap must be put\r back on the pen after each injection in order to protect from light.<\/span><\/p>","ID":"9889234e-bf12-4bcb-8be7-d807a66ce404","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pen cap must be put\r back on the pen after each injection in order to protect from light.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f4614dc4-40e0-4be0-8661-1bb4a634c8a4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p>","ID":"b6927c63-1687-45e6-80fb-50d5a19667ea","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><\/p>","ID":"6e699f30-5b17-4e9d-8cea-448c72c28b56","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Store in a refrigerator\r (2 \u00b0C \u2011 8 \u00b0C).<\/span><\/p>","ID":"524902bb-9455-45b2-a0d8-ddefe920ad7d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Store in a refrigerator\r (2 \u00b0C \u2011 8 \u00b0C).","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"4a14a6f4-25ed-459d-be6f-49bfac446eee","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Do not freeze.<\/span><\/p>","ID":"3563b751-116f-4486-ad98-70924880c8a5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not freeze.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0c1e6b39-64e4-4285-afaf-9bf641356116","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Keep the cartridge in\r the outer carton in order to protect from light.<\/span><\/p>","ID":"85a4601d-8194-456d-b886-09293c791f76","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Keep the cartridge in\r the outer carton in order to protect from light.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"149a64af-b595-494a-99bb-ae35e97a4736","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Before opening and\r within its shelf life, the medicinal product may be removed from the\r refrigerator, without being refrigerated again, for up to 3 months. Do not\r store above 25 \u00b0C. The medicinal product must be discarded if it has not\r been used after 3 months.<\/span><\/p>","ID":"ca1dee61-7fa0-4e43-a7c9-23c3f2535824","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Before opening and\r within its shelf life, the medicinal product may be removed from the\r refrigerator, without being refrigerated again, for up to 3 months. Do not\r store above 25 \u00b0C. The medicinal product must be discarded if it has not\r been used after 3 months.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1f8fe518-5f1a-4e88-8276-7a32612b8809","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after first opening\r of the medicinal product, see section 6.3.<\/span><\/p>","ID":"967e0d9e-e4eb-42f3-a1bc-1100d0bdb129","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For storage conditions after first opening\r of the medicinal product, see section 6.3.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"35dd3658-12d6-4ba8-8a95-83c9ff2ba3a6","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p>","ID":"3f39db73-e78c-4612-b1c6-bde5ff86012d","Styles":"None","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature and contents of container","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"db511719-423a-4675-b461-6ff1346977cb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/u><\/p>","ID":"7cecc3b7-54f1-478b-8b86-5d0872b21517","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 300 IU\/0.5 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 0.5 mL of solution.<br\/>\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")<\/span><\/p>","ID":"8a1a220e-5484-42c6-812d-01827aeed7ba","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 0.5 mL of solution.\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p>","ID":"10913380-a8b8-4e38-899b-d9de722379f7","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pack size of\r 1 cartridge and 10 injection needles.<\/span><\/p>","ID":"e956a147-287e-4ea3-a0a5-c7b7f1fb9b30","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pack size of\r 1 cartridge and 10 injection needles.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p>","ID":"8b28b4e4-fdac-4f88-b25e-4d1de6879384","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"7b20714f-6bf6-44b5-8266-940bf38cc183","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0def6170-26e3-419a-adc0-2d494ef2525b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/u><\/p>","ID":"33cc1467-07c7-4082-89ec-6dcd3236a048","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 450 IU\/0.75 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 0.75 mL of solution..<br\/>\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")<\/span><\/p>","ID":"9f0667e2-b680-4cb0-ba52-92b521142c35","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 0.75 mL of solution..\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pack size of\r 1 cartridge and 10 injection needles.<\/span><\/p>","ID":"9eeb30ea-7666-4207-b2d9-7aac072f9ff1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pack size of\r 1 cartridge and 10 injection needles.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><\/p>","ID":"78cb75c1-a7a5-4975-bb39-fc3ec8a6b3d5","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"0b34a277-3731-4120-b9b2-9849cafdd65e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"2036413c-7e50-4edc-82b6-bcb85f877213","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 900 IU\/1.5 mL solution for injection<\/span><\/u><\/p>","ID":"c7a9287e-6ccd-407f-a893-b16abfd7c6c1","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 900 IU\/1.5 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:black\">Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 1.5 mL of solution..<br\/>\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")<\/span><\/p>","ID":"81221aa7-8eae-430f-8893-2d20b911f74e","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartridge (type I glass) with a rubber piston (bromobutyl\r rubber) and a crimp\u2011cap (aluminium) with a septum (bromobutyl rubber),\r containing 1.5 mL of solution..\r Injection needles (stainless steel; 0.33 mm x 12 mm,\r 29 G x \u00bd\")","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5f93bff5-df8f-4fd2-98c0-51967a2d06fd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Pack size of\r 1 cartridge and 20 injection needles.<\/span><\/p>","ID":"18709c38-6949-4a7a-a8da-df10c2bf295d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pack size of\r 1 cartridge and 20 injection needles.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"665eb4c0-9293-45f9-a774-15399c4490d2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"f31e20ef-6008-45ee-abfc-8b9c7a4d33fb","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"607b5b1a-6841-4ebc-b999-1aaebdfaad46","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1c89ac33-0f83-429e-a519-6ed87269c711","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and\r other handling<\/span><\/b><\/a><\/p>","ID":"66ddc004-2421-4a25-bca9-de266e56f21d","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal and\r other handling","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"f8ad7947-84cf-4e0e-ac38-0400b2f2cf90","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">No special requirements for disposal.<\/span><\/p>","ID":"9dadaf22-409b-435e-a1f0-15a7a4eacf97","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No special requirements for disposal.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e334e52f-ce94-46a0-96d3-29c5186788b2","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">The solution must not\r be used if it contains particles or if the solution is not clear.<\/span><\/p>","ID":"1583c704-e05e-4131-8041-b71d27030909","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The solution must not\r be used if it contains particles or if the solution is not clear.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e9a85788-bdb6-4cdf-be94-89f3c58107f3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Ovaleap is designed for\r use in conjunction with the Ovaleap Pen only. The instructions for use of the\r pen must be followed carefully.<\/span><\/p>","ID":"bdb19fa6-3dfb-4142-a9b3-a213f37bd140","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ovaleap is designed for\r use in conjunction with the Ovaleap Pen only. The instructions for use of the\r pen must be followed carefully.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"3e2ea715-0c9d-41f7-984d-0dfeca6e1ec5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Each cartridge must be\r used by a single patient only.<\/span><\/p>","ID":"ffb70cd7-c8c1-4741-b001-a60720a32d60","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each cartridge must be\r used by a single patient only.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bdd3516b-a42b-45f9-961c-2ae618879a62","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Empty cartridges must\r not be refilled. Ovaleap cartridges are not designed to allow any other\r medicinal product to be mixed in the cartridges. Discard used needles\r immediately after injection.<\/span><\/p>","ID":"209f7a91-6177-478c-9b9e-33a2cf8d5542","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Empty cartridges must\r not be refilled. Ovaleap cartridges are not designed to allow any other\r medicinal product to be mixed in the cartridges. Discard used needles\r immediately after injection.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e90b0d52-a549-4d15-a74c-a6fffb90a976","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"18ff8cdc-c3da-4392-81ff-efc703e6df2e","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p>","ID":"62be524b-2775-43e6-9811-97905f1c65ff","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"60b26910-0ef1-4b06-bf1a-fe0910db4115","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"NL\">Theramex Ireland Limited<\/span><\/p>","ID":"21c89b63-0081-463d-92d0-569c4aeecb0d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Theramex Ireland Limited","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">3<sup>rd<\/sup> Floor, <\/span><span lang=\"NL\">Kilmore House,<\/span><\/p>","ID":"d0170c01-f088-40e1-9460-42e49e8ee834","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3rd Floor, Kilmore House,","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"NL\">Park Lane, Spencer Dock,<\/span><\/p>","ID":"5a5645b8-576f-4893-9022-43acb5d24453","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Park Lane, Spencer Dock,","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"NL\">Dublin 1<\/span><\/p>","ID":"4103acc7-3114-4e86-aae2-c9acbcee3059","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dublin 1","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"NL\">D01 YE64<\/span><\/p>","ID":"b70f3043-953e-4c6c-900e-d16c9d1010a3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"D01 YE64","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"NL\">Ireland<\/span><\/p>","ID":"443f8f0a-60a8-4f0a-bc4c-4976ffffee55","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Ireland","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"52bd51a2-1ca1-43d7-8cc2-113d622f794d","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"d083bdf1-8fa5-4ac0-a5c3-d73cfcc9e4c3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">8.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p>","ID":"88b51864-3730-4649-925f-d48385918a74","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBER(S) ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7b7c0ef1-e8bb-400c-8c4f-2d023c580369","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 300 IU\/0.5 mL solution for injection<\/span><\/u><\/p>","ID":"6d5a66d9-786f-4b83-842c-d8fc0f11cf35","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 300 IU\/0.5 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/001<\/span><\/p>","ID":"bbf175e3-f0a6-4e39-bfa8-f9c1e48507e4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/13\/871\/001","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"707a290a-310c-422b-ab4a-a49ea923a732","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap\r 450 IU\/0.75 mL solution for injection<\/span><\/u><\/p>","ID":"0ac13000-5cec-4659-b0d2-324c9b0435df","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap\r 450 IU\/0.75 mL solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/002<\/span><\/p>","ID":"c6842466-bc7b-49c2-9b6e-a1bafbdc6a75","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/13\/871\/002","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"0b0a4d4e-a0df-4884-a4d1-55041843b0c3","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><u><span lang=\"EN-GB\" style=\"color:black\">Ovaleap 900 IU\/1.5 mL\r solution for injection<\/span><\/u><\/p>","ID":"d97be9ed-042e-4fdd-a290-5051ecc20160","Styles":"text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ovaleap 900 IU\/1.5 mL\r solution for injection","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU\/1\/13\/871\/003<\/span><\/p>","ID":"c658d633-e420-4add-a7b8-33e3c7ad2276","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/13\/871\/003","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"78cced23-76da-4b3b-b05b-e1c7ffa82adf","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"79550710-23e5-4f45-b4aa-d5e6a2581cfa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p>","ID":"ad3bce8a-ed71-4762-914c-24a25eda327a","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"41cc3706-a356-4607-b4bb-fffa05433b1c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:black\">Date of first\r authorisation: 27 September 2013.<\/span><\/p>","ID":"86d319d9-34ae-469b-ae06-1b77fb702be8","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first\r authorisation: 27 September 2013.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 16 May 2018.<\/span><\/p>","ID":"3131689a-b138-4751-9ccb-b44b150f8c53","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of latest renewal: 16 May 2018.","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bc2a66dd-804e-4c9c-80eb-4defc273c59c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"5a197ce7-e837-41f3-b392-5aa28d021fa9","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p>","ID":"aa0a1ac3-fd4b-4944-a778-1312509e5ff8","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"498d6c49-75c8-4946-9353-fce5e1fe4aa1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Detailed\r information on this medicinal product <\/span><span lang=\"EN-GB\">is available on\r the website of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext;text-decoration:\r none\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">. <\/span><\/p>","ID":"fa720a2e-b8b4-4041-b1f6-0bb0acfadf7a","Styles":"margin-right:-.1pt","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed\r information on this medicinal product is available on\r the website of the European Medicines Agency http:\/\/www.ema.europa.eu. ","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"19a55011-b696-4eaf-a32e-c9739b0cfc22","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"296e9317-9e70-4837-8a70-6c7f98c9bee4"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"216704a5-abac-4460-b3d9-83593ebcb556","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"19a55011-b696-4eaf-a32e-c9739b0cfc22"}]